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Autophagy is the process of “cell self-eating” which has been implicated both in 
cell survival and cell death.  Sphingosine kinase 1 (SphK1) regulates the intracellular 
balance between ceramide and sphingosine, bioactive lipids associated with cell death, and 
sphingosine-1-phosphate (S1P), whose actions are associated with survival and 
proliferation.  Previous studies have implicated upregulation of SphK1 in the induction of 
autophagy.  In this study, SK1-I, a SphK1 specific competitive inhibitor, induced 
autophagy in a concentration and time dependent manner in HCT116 colorectal carcinoma 
cells.  This autophagic response was observed to be more intense in wild type p53 
   
 xii
expressing HCT116 cells than in p53 null cells and ultimately led to non-apoptotic death in 
wild type and apoptotic death in p53 null cells. In agreement, cell death in wild type cells 
was not accompanied by cleavage of polyADP ribose polymerase, a hallmark of apoptosis. 
Knockdown of Beclin 1 demonstrated that it and its binding partners do not have a 
significant role in the induction of autophagy in response to SK1-I treatment.  Similarly, 
mTORC1 signaling was not observed.  In contrast, SK1-I markedly decreased Akt 
phosphorylation. However, this might not be the sole factor important for SK1-I induced 
autophagy, as pharmacological inhibition of Akt only led to a comparatively weak 
autophagic response.  Indeed, phosphorylation of the endoplasmic reticulum (ER) stress 
marker eIF2 α, was greatly reduced, suggesting that an ER mediated mechanism also 
contributes to SK1-I induced autophagy. Thus, SK1-I induced autophagy was likely 
triggered by ER stress signaling and led to non-apoptotic cell death in the more highly 
autophagic wild type 53 expressing cells. These results suggest that an isotype specific 
SphK1 inhibitor might be a useful adjunct for the treatment of cancer or other diseases in 
which enhancement of cytotoxicity or autophagy is desirable.   
  14 
 
 
 
 
 Introduction 
 
 
Autophagy  
Autophagy is catabolism of a cell's own contents through lysosomal degradation.  
Four broad categories of autophagy have been described: microautophagy, crinophagy, 
chaperone mediated autophagy and macroautophagy1, 2. These forms differ in their 
identification and trafficking of substrates to the lysosome.   In microautophagy, the 
lysosomal membrane directly engulfs its substrate3.  In crinophagy secretory vesicles fuse 
with the lysosome4.  In chaperone mediated autophagy, cytosolic chaperones (Hsc70 
complex) deliver proteins directly to the lysosome based on a pentapeptide consensus 
motif within the substrate5.  Macroautophagy, the form of autophagy investigated in this 
study (henceforth referred to as autophagy), involves the formation of a distinctive double 
membraned vesicle, the autophagosome, which first envelops a portion of intracellular 
contents including cytosol and organelles6 , matures, then fuses with the lysosome. 
 
Roles of Macroautophagy 
 Mammalian macroautophagy most commonly occurs in response to nutrient 
starvation and acts to support cell survival.  Amino acid starvation (differing based upon 
the tissue and amino acid)7 and growth factor withdrawal 8 have been shown to induce an 
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autophagic survival response.  At the organismal level, nutrient starvation-induced 
autophagy is proposed to be hormonally controlled, as, for example, in the liver, where 
suppression of autophagy by insulin and induction of autophagy by glucagon is observed9 . 
 It is also well known that basal autophagy plays an important housekeeping role as 
the primary mechanism for degradation of long-lived proteins7 .  Accordingly, it has been 
proposed that induction of autophagy could be a treatment for neurological disorders such 
as Huntington's, Alzheimer's, and Parkinson's diseases by degrading abnormal protein 
accumulations10, 11 .  Autophagy has also been theorized to support immune major 
histocompatibility complex 1 and 2 formation through the engulfment and degradation of 
intracellular pathogens12 .   
 Observations of autophagy induction by nutrient starvation, and the housekeeping 
role of autophagy in degrading long-lived proteins have led to the characterization of 
autophagy as a process of nonspecific mass degradation.  Recently, however, it has been 
noted that mammalian autophagy plays a role in regulating intracellular homeostasis, 
including that of reactive oxygen species (ROS)13-16 and attenuating the effects of 
pathogenic intracellular bacteria and viruses17 .  Proteomic analysis of autophagic cells 
indicates that degradation of cell contents via autophagy appears to be regulated at the 
protein complex/organelle level in a manner specific to the conditions triggering the 
autophagic response18 . 
 In keeping with this emerging homeostatic, organelle-focused understanding of 
autophagy, changes in endoplasmic reticulum homeostasis, related to both calcium release 
and protein misfolding, strongly influence autophagic response19 .  Furthermore, several 
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autophagy-related proteins appear specifically localized to the ER18, 20, 21 .  These 
characteristics of autophagy induction and localization will be considered in the following 
sections and may lend further insight into the mechanisms regulating autophagy.   
 In opposition to the homeostatic role proposed for autophagy, numerous recent 
studies have used inhibition of autophagy by the phosphatidylinositol 3-kinase (PI3Kinase) 
inhibitor 3-methyladenine (3MA) and downregulation of expression of autophagy related 
proteins to demonstrate that inhibition of autophagy prevents cell death under conditions 
which normally elicit non-apoptotic death22 .  These observations have been used to assert 
that autophagy is capable of inducing cell death in a non-apoptotic fashion.   
 The dichotomous role of autophagy in cell survival has become an important issue 
in understanding tumorigenesis23 .  Although autophagy appears to suppress tumor 
development in animals, its pro-survival role during nutrient scarcity may be essential for 
the survival of quickly proliferating tumor cells.  Evidence that autophagy related genes are 
frequently deleted in cancer, and that cancer cells seem deficient in autophagy, suggest that 
autophagy is anti-tumorigenic.  Several oncogenes, such as Bcl-2 and Akt, have been 
shown to play a central role in attenuating autophagy, while tumor suppressor genes, such 
as DAPK and Beclin 1, are pro-autophagic.  In addition, chemotherapeutic agents, such as 
rapamycin have been shown to function via an autophagic killing mechanism24 .  Even so, 
the possibility exists that the autophagic response in these conditions is engaged to 
promote survival rather than death. 
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Autophagosome Formation and Maturation 
 The structural, enzymatic, and mechanistic elements of autophagy induction are 
beginning to be understood.  These elements have typically been characterized as 
contributing to one of two phases of the autophagic process: autophagic vesicle formation 
or autophagosome maturation. 
 
Autophagosome Maturation 
 While Atg5, LC3, and perhaps Beclin 1 complexes are now considered essential in 
regulating initial autophagic vesicle formation25-27, enclosed vesicles undergo maturational 
changes leading to lysosomal fusion under the regulation of another, possibly distinct, set 
of factors.  During maturation, autophagosomes acquire lysosomal membrane proteins, 
experience an increase in cholesterol content in their outer membrane and become more 
acidic28-31.  It has been proposed that in mammals this maturation process occurs through 
autophagosome fusion with early and late endosomal vesicles31.  It has been observed that 
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) protein, known to be 
involved in receptor regulation by endocytosis32, localizes to autophagosomes and its 
deletion inhibits autophagolysosme formation and multivesicular endosome formation33.  
Similarly, in mouse, a dominant negative form of suppressor of potassium transport growth 
defect 1 (SKD1, an ATPase) inhibits fusion of autophagosomes with endosomes causing a 
deficit in bulk protein degradation34.  Fusion of autophagosomes with lysosomes in yeast is 
inhibited by knockdown of Rab7 small GTPase 35, 36 and Vti1p SNARE protein37.  
Lysosome Associated Membrane Protein 1 and 2 (LAMP1 and 2), which constitute the 
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majority of lysosomal membrane proteins, are also thought to be involved in 
autophagosome fusion.  However, its knockout increases autophagosome and cholesterol 
accumulation without attenuating long-lived protein degradation29.  Throughout this 
process, microtubules are thought to play a role in the production of autophagosomes.  It 
has been noted that microtubules carry autophagosomes toward the microtubule-organizing 
center38.  Furthermore, traffic of autophagosomes requires cytoplasmic, microtubule-
associated, histone deacetylase 639. 
 In mammalian cells, autophagic vesicle formation has commonly been associated 
with the activity and localization of three autophagy related proteins (Atg): Atg5, LC3 
(Atg8), and Beclin 1(Atg6).  The precise roles of these proteins in forming the 
autophagosome, however, are not yet well understood. 
 
Atg5 
 Atg5 is a member of the Atg family first identified in yeast.  Atg5 has been shown 
to be necessary for survival in mice40 and has recently been implicated in both autophagy 
and apoptosis (after calpain cleavage)41.  Atg5 protein capable of conjugation to another 
Atg protein, Atg12, is necessary for elongation of the isolation membrane (initiation of 
autophagosome formation) in mammals25 (Fig. 1).  
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Figure 1: Atg5 and LC3II contribute to early formation of the autophagosome.42  
Beclin1 in complex with type 3 phosphotidyl inositol 3 phosphate kinase produces 
phosphatidyl inositol 3 phosphate (PtdINs3P), considered necessary for autophagosome 
formation and implicated in the localization of the isolation membrane.  Atg12-Atg15 
(autophagy protein) are shown to be necessary for autophagosome formation and act as E3 
type ligases for lipidation of LC3I to LC3II.  LC3II is necessary for elongation and 
completion of the autophagic vesicle.  Atg5-Atg12 leaves the isolation membrane when it 
closes to form the autophagosome.  LC3II is completely shed and degraded from the 
autophagosome after fusion with the lysosome. 
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In this ATP dependent process, Atg12 ubiquitin-like protein is covalently conjugated to 
Atg5 via the E1-ligase activity of Atg7 and the E2 like activity of Atg1043-47.  The Atg5-
Atg12 complex has been shown to localize to autophagosome precursors (the isolation 
membrane) and to dissociate from the autophagosome upon closure of the autophagic 
vesicle (isolation membrane)48.  Atg5 is in complex with Atg16L and Atg12, yet 
knockdown of each of these proteins inhibits autophagosome formation at different 
stages49.  Nonetheless, this complex has been shown to play necessary role in the next step 
of this process, LC3 lipidation. 
 
LC3 
 LC3 is a soluble, microtubule associated protein50 that was observed to associate 
with the inner and outer membrane of the elongating autophagosome26.  For completion of 
the autophagic vesicle, cytosolic LC3I (Atg4 cleaved LC3) must be covalently conjugated 
to phosphatidyl-ethanolamine to form LC3II, a ubiquitin-like modification requiring Atg7 
and Atg351.  In yeast and mouse, the Atg5-Atg12 conjugate functions as an E3-like enzyme 
for this lipidation reaction48, 52.  In addition, the Atg5-Atg12 dimer binds Atg16L, homo-
oligomerizing to form 800 kilodalton complexes in mammals53, 54.  The intracellular site of 
LC3 lipidation appears to be determined by the localization of the Atg16L complex.  
Ectopic LC3 lipidation can be induced by changes in Atg16L localization49.  In humans, 
Atg16L1, a single common coding variant of this protein, predisposes individuals to 
development of Crohn's disease (an inflammatory illness of the digestive tract) and shows 
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impairment in the capture of Salmonella within autophagosomes55.  This LC3 lipidation 
system is also implicated in lipid droplet formation56.        
 LC3II, although targeted to the Atg5-Atg12 associated autophagosomal precursors, 
is retained in the outer leaflet until autophagosome maturation36 and is thought to be 
degraded on the inner leaflet only with lysosomal fusion57.  As such, it has proven to be an 
important marker for pre-lysosomal autophagosomes. 
 
Beclin (Atg6) 
 Beclin1 is a well characterized tumor suppressor gene27, 58 homoallelically deleted 
in many human tumors.  In breast cancer, Beclin1 haploinsufficiency causes defective 
autophagy, but restoration of Beclin1 induces autophagy and inhibits tumorigenicity27.  
Beclin 1's autophagic role is thought to be as binding partner of Vps34 type 3 PI3Kinase59.  
The association of Beclin 1 with Vps34 has been shown to induce the production of lipid 
scaffolding molecule phosphatidylinositol 3-phosphate (PI3P) which is considered 
necessary for autophagosome nucleation59.  In yeast, Beclin1 orthologue-produced PI3P 
has been suggested to recruit proteins required for autophagosome formation based on 
association with FYVE or PX motifs60, 61.  In rat cerebral cortex, Beclin 1 appears to 
localize to membrane rafts and dissociates from them during traumatic brain injury induced 
autophagic events62.  In HCT116 colon cancer cells, Beclin 1 localizes to mitochondria and 
nucleus63 other eukaryotic cells, Beclin 1 has been observed to localize to the trans-Golgi 
and ER that serve as foci of PI3P formation59.  Serine threonine kinase p150 may mediate 
this membrane association of the Beclin 1 PI3kinase complex64.   
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 A number of Beclin1 binding proteins regulate the induction of autophagy through 
their influence on the association of Beclin1 with Vps34.  This association is positively 
regulated by UV radiation resistance-associated gene tumor suppressor (UVRAG) and the 
activating molecule in Beclin 1-regulated autophagy protein 1 (Ambra1)65, 66 resulting in 
increased induction of autophagy.  In HCT116 cells, a heterozygous mutation inhibits 
UVRAG activity and restoration of UVRAG increases autophagy and attenuates cell 
proliferation65.         
 Binding of Bcl-2 to Beclin1's Bcl-2 homology domain (BH3 domain) is a second 
and critical mechanism by which Beclin1's induction of autophagy is regulated.  Binding 
of Bcl-2 to Beclin1 impedes the association of Beclin1 with Vps34.  Furthermore, Bcl-2-
binding-defective Beclin 1 mutants induce autophagy leading to caspase-independent 
autophagic cell death67.  Specific Bcl-2 localization to the ER blocks autophagosome 
accumulation in response to Xestospongin B (an inositol 1,4,5-triphosphate receptor 
(IP3R) inhibitor), vitamin D analogue EB1089 (inducer of ER calcium release), ATP 
depletion, and starvation20, 59, 68, whereas localization to other intracellular compartments 
does not.   As such, Bcl-2 has emerged as the principal negative regulator of Beclin1 
activity. 
  Bcl -2 binding to Beclin1 is itself mediated by two mechanisms.  The first is 
competitive inhibition of Bcl-2 Beclin 1 binding by other BH3 proteins.  This was 
demonstrated using Bad and BH3 mimetic compound ABT737.  While BH3 binding of 
Bcl-2 is capable of inducing autophagy of mitochondria, it is not capable of inducing 
autophagy in the ER (notwithstanding its ability to disrupt ER Beclin1-Bcl-2 complexes)20 
   
23 
 
.  The second mechanism by which Bcl-2 binding appears to be regulated is through 
phosphorylation of Bcl-2.  In response to tamoxifen and starvation, Pattingre et al. 
observed increased accumulation of autophagic vesicles.  This was explained by induction 
of Bcl-2 phosphorylation which caused its dissociation from Beclin 1.  Ceramide activation 
of cJun N-terminal kinase (JNK) was required to phosphorylate Bcl-2 and to stimulate 
autophagy69.   
 Beclin1's presence in the ER also allows it to interact with the IP3R (an ER 
membrane calcium channel) which, when in complex with Beclin1, appears to inhibit the 
induction of autophagy.  This effect is increased by overexpression and binding of Bcl-221 .  
Furthermore, autophagy induced by pharmacological inhibition of receptor activity or 
IP3R downregulation due to nutrient starvation, is both Calcium and mTORC1 
independent21 .  
 Interestingly, one case of Beclin 1 independent autophagy has been observed.  
Scarlatti et al. reported that Resveratrol, a phytoalexin with anti-cancer properties produced 
by plants in response to bacterial infection, causes an increase in autophagy in MCF7 cells.  
Knock down of Beclin 1 and Vps 34, and inhibition of Vps34 using specific inhibitor 3 
methyladenine (3MA), had no effect on autophagic vesicle formation or degradation of 
long-lived proteins in Resveratrol treated cells70 .   
 
Signaling Mediators of Autophagy 
 Potential upstream mediators of autophagosome formation integrate signals 
encoding the health of the cell and its environment. Two integrative signaling factors have 
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been shown to significantly correlate with autophagic induction.  In many cases, these 
factors appear closely intertwined, suggesting that their interactions act as the cellular 
circuitry for deciding whether or not to mount the autophagic response.  The first is 
mammalian target of rapamycin (mTOR). 
 
mTOR 
 mTOR has been characterized as forming two complexes: mTORC1 and 
mTORC271, 72.  mTORC1 is composed of raptor (scaffolding protein), PRAS40 and 
mLST873.  Activity of the complex is directly inhibited by treatment with rapamycin which 
binds raptor and disrupts its interaction with mTOR74. 
 mTORC1 is thought to integrate a number of nutrient and growth factor pathways 
including those containing Akt75, ERK76, AMP kinases77 and Rsk178.  Sancak79 theorized 
that in response to signaling events upstream, Rag small GTPase complex binds to Raptor 
which stimulates mTOR by changing localization of mTORC1 to perinuclear 
endomembrane structures where mTORC1 can be activated by Rheb small GTPase.  The 
specific mechanism of activation is unknown.  The direct substrates of mTORC1 are 
p70S6Kinase, 4E-BP180,81, and Pras 4082.  P70S6 kinase, in turn, is the major protein 
kinase responsible for mTOR ser-2448 phosphorylation83 .   
 Direct mTORC1 inhibition by rapamycin has been shown to induce autophagy. 
mTORC1 inhibition is necessary for nutrient starvation induced autophagy84-86.  Elevated 
mTORC1 activity results in cells with impaired ability to initiate autophagy in response to 
nutrient starvation85.  Reduced mTORC1 activity has been observed in autophagic cells as 
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a result of ER stress associated with calcium activated AMPK signaling68, and JNK 
upregulation87, elevated SphK1 expression88, elevated ceramide levels69, and Safingol a 
SphK1 and PKC inhibitor89.  Nonetheless, changes in mTORC1 activity have not been 
observed in autophagy induced by PKCθ in response to calcium90, or IP3R in response to 
reduction in IP3R expression91.      
 mTORC2 is composed of mTOR, rictor, mSin1, mLST8 and PRR592-95.  In 
response to growth factors but not nutrients, mTORC2 phosphorylates Akt on serine 473 95 
(this may be a separate population of Akt than that upstream of mTORC1).    In addition, 
turn motif phosphorylation involved in folding of Akt and conventional PKC is dependent 
on mTORC2 function96.  Overall, mTORC2 activity has been primarily associated with 
actin cytoskeletal rearrangement involving PKCα and GTPases Rho and Rac which signal 
through unknown effectors97, 98.  Recently mTORC2 has proven to have direct relevance to 
autophagy as well.  mTORC2 inhibition induces FoxO3 transcription of BCL2/adenovirus 
E1B 19kDa interacting protein 3 (BNIP3)99, a BH3-only protein100 whose upregulation is 
necessary and sufficient for induction of autophagy. 
 
Endoplasmic Reticulum 
The endoplasmic reticulum also appears to have a central role in regulating 
autophagy (Fig 2).  In addition to localization of Beclin and its binding partners to the ER, 
changes in ER homeostasis mediated by factors regulating the unfolded protein response 
and ER calcium balance, also induce autophagy.  The ER is a central regulatory apparatus 
for protein folding and trafficking, intracellular calcium homeostasis, and synthesis of 
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unsaturated fatty acids, sterols and phospholipids.  Disruption of any of these functions 
results in ER stress101.  Increasingly, the sensors of ER homeostasis have been implicated 
in the induction of autophagy.  Homeostatic imbalances of the ER are caused in different 
ways by a variety of pharmacological agents: thapsigargin disrupts ER calcium 
homeostasis, tunicamycin  inhibits protein n-glycosylation, Brefeldin A blocks protein 
transport to the Golgi, polyglutamine proteins form protein aggregates 102 and long chain 
lipid molecules, such as palmitate103, induce decreases in luminal calcium104.  In response 
to these insults, three membrane proteins act as parallel sensors triggering transcriptional 
effects: protein kinase r-like ER kinase (PERK), which phosphorylates eukaryotic 
initiation factor 2α (eIF2α) and induces C/EBP homologous protein  (CHOP) 
transcription105, inositol-requiring kinase 1 (IREα1), which binds tumor necrosis factor 
receptor-associated factor 2 (TRAF-2) inducing splicing of XBP-1 transcription factor and 
stimulating JNK activity101, and activating transcription factor 6 (ATF6), which 
translocates to the nucleus and induces transcription of ER-specific member of heat shock 
protein 70 family Grp78/BiP (Glucose Response Protein 78/Binding Immunoglobulin 
Protein)106.  Each appears to have differential sensitivity to stress stimuli, PERK being 
activated most quickly in response to calcium changes, PERK and IREα1 responding 
equally quickly to protein misfolding, and ATF6 responding slowly to protein 
misfolding107.  It has been theorized that ER chaperone GRP78/BiP mediates this effect 
through its binding inhibition of PERK, IREα1 and ATF6.  BiP is also required for stress-
induced autophagy108. 
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 Figure 2:  ER stress pathways implicated in autophagy109 There are three ER 
stress responsive proteins whose activity appears to be affected by ER calcium levels, 
accumulation of misfolded proteins, inhibition of transport from the ER etc., disruptions of 
ER equilibrium which are known to result in changes in transcription that define ER stress.  
They are: protein kinase r-like ER kinase (PERK), activating transcription factor 6 (ATF6), 
and inositol-requiring  kinase 1 (IRE1).  While ATF6 knockdown has not been shown to 
affect autophagy in response to ER disequilibrium, knockdown of PERK and IRE1, along 
with eIF2alpha and JNK downstream targets, has been shown to inhibit autophagy and are 
therefore thought to be necessary for autophagy in response to different forms of ER stress.  
Independent of these three proteins are autophagic responses to cytosolic calcium increases 
which can be induced by calcium release from the ER and are calcium/calmodulin 
dependent kinase kinase-beta (CaMKKBeta), AMP kinase, and mTOR dependent.  Direct 
inhibition of ER-bound inositol (1,4,5) triphosphate receptor also appears to induce 
autophagy. 
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 Both PERK and IREα1 have been found necessary for induction of autophagy.  In 
one case, PERK and eIF2α were required for autophagic response induced by aggregation 
of polyglutamine repeat proteins, but IREalph1 and ATF6 were not102.  Alternatively 
IREα1, TRAF2 and JNK were required for autophagy in response to thapsigargin and 
tunicamycin, while PERK and ATF6 were not110. 
 It has been proposed that increased cytosolic calcium due to ER calcium release is 
responsible for autophagy signaling by the ER68.  Calcium release from the ER can be 
induced by a number of different agents, including vitamin D analogues, thapsigargin 
inhibition of ER calcium transporter (SERCA)111, ATP induced opening of IP3R 
channels68 , and accumulation of unfolded proteins in the ER lumen112.  
 One explanation of ER calcium release induced autophagy attributes regulation of 
this response to calcium/calmodulin-dependent kinase kinase-beta activation of AMPK 
that leads to inhibition of mTORC168.   
 Another possibility is PKCθ phosphorylation which is required for the ER-stress 
induced autophagic response but unnecessary for amino acid starvation induced autophagy.  
PKCθ phosphorylation induces autophagy in a calcium dependent manner independent of 
mTORC1.   PKCθ phosphorylation is not dependent upon ER sensors PERK, IRE1 or 
ATF6, but its autophagic effect is inhibited by knockdown of IRE1 and eIF2α90.  
 Increases in cytosolic calcium also activate the death associated protein kinases 
(DAPK)113 and calpain proteases114, both of which induce autophagosome formation.   
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Sphingosine-1- Phosphate (S1P) 
S1P is a bioactive lipid signaling molecule containing a sphingoid long chain base 
attached to a phosphate group.  S1P has been shown to have a remarkable array of roles 
within the cell.  Once considered only the end metabolite of all sphingolipids, it is now 
known to regulate cell growth115, 116, suppress apoptosis117, contribute to cytoskeletal 
rearrangements and cell motility118-120, invasion, angiogenesis and vascular maturation121, 
122, and trafficking of lymphocytes123.  It has also been proposed to play an important role 
in the regulation of intracellular calcium124, which may contribute to its varied influences.  
By contrast, its precursors, ceramide (N-acylsphingosine) and sphingosine are associated 
with cell-growth arrest, stress responses, and apoptosis.  Thus a regulatory balance has 
been theorized between S1P and ceramide125.    
 Many of the effects of S1P are mediated by five G-protein coupled receptors (S1P1-
5) for which S1P and dihydroS1P are the high affinity ligands125.   The varying effects of 
S1P have been ascribed to the differential distribution of these receptors on each cell and 
their differential coupling to G proteins.  S1P1 couples to Gi126, S1P3-5 to Gi or G12/13 and 
S1P2 may couple to Gs, Gq or G12/13127.  This engages signaling cascades which involve 
small GTPases128, adenylate cyclase127, inhibition of phospholipase C 129 or inhibition of 
Akt and ERK1/2 phosphorylation130, 131.  In addition, cells are capable of secreting S1P, 
which is thought to act in an autocrine/paracrine fashion on these receptors132.  Little, 
however, is known about S1P's intracellular targets. 
S1P is not biosynthesized de novo and can only be formed from sphingosine 
produced during turnover of complex sphingolipids by phosphorylation catalyzed by two 
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sphingosine kinase isoenzymes, SphK1 and SphK2 (Fig. 3).  De novo ceramide synthesis 
begins with the rate limiting condensation of L-serine with palmitoyl-CoA at the cytosolic 
leaflet of the ER133.  The product, 3-keto-sphinganine, is reduced and N-acylated to 
dihydroceramide.  A trans 4,5 double bond is inserted into dihydroceramide by desaturase 
to form ceramide134. Inhibition of this desaturase produces non-Beclin dependent 
autophagy135. Ceramide production can be induced by hypoxia, various pharmacological 
agents and tumor necrosis factor α136, 137.  Ceramides are shuttled to the Golgi by CERT, a 
cytoplasmic protein with a phosphatidylinositol-4-phosphate binding domain138.  
Ceramides are then converted into sphingomyelins by sphingomyelin synthase on the 
lumenal side of the Golgi, or to glucosylceramides (whose accumulation is associated with 
lysosomal storage disorders) on the cytosolic surface of the Golgi139.   
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 Figure 3:  Sphingolipid Synthesis 140  Sphingosine 1 Phosphate (S1P) is the 
product of sphingosine (Sph) phosphorylation by sphingosine kinases (SK) which occurs at 
the plasma membrane and may also occur at other intracellular locations.  Sph is the result 
of removal of a fatty acid chain from ceramide (cer).  Ceramide is synthesized via 
sphingomylin (SM) recycling by sphingomylinases (SMase) at the inner and outer leaflets 
of plasma membrane, lysosome, and perhaps other sphingomylin containing membranes 
(such as of the mitochondria) and via a denovo synthesis pathway involving the ER (which 
begins with condensation of L-serine, Ser, with palmitoyl-CoA, palmityl CoA, to produce 
3-keto-sphinganine, 3KdhSph, which is reduced to dihydrosphingosine ,dhSph, and N-
acylated to dihydroceramide, dhCer, which is desaturated to ceramide).  Ceramide from 
denovo synthesis is transported to the Golgi via CERT and between golgi compartments 
via FAPP2.  Golgi ceramide is modified to form SM and glucosylceramides (GluCer) used 
to form other glycosphingolipids (GSL). 
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GlcCer is transported between Golgi compartments by FAPP2141.  Sphingomyelin, 
which is localized to cell membranes throughout the cell, is an important structural lipid 
and serves as a reservoir for ceramide for the synthesis of sphingosine and S1P.  This 
function is performed by neutral, acid, and alkaline sphingomyelinases142 and is rapidly 
increased by chemotherapeutic agents, ultraviolet irradiation and other cell stresses143, 144.  
To produce sphingosine, ceramidase removes the fatty acid chain from ceramide142. The 
ATP dependent synthesis of S1P follows, accomplished by SphK1 and SphK2.  
Ultimately, S1P is dephosphorylated back to sphingosine by S1P phosphatase isotype 1 or 
2 which reside in the ER145, 146.  S1P can also be degraded by an integral ER membrane 
protein, S1P lyase, forming hexadecenal and phosphoethanolamine which is reused for the 
biosynthesis of phosphatidylethanolamine147 . 
 
SphK2 
The most recently identified isotype of sphingosine kinase is SphK2.  Although we 
will be considering the role of a SphK1 specific inhibitor, SphK2 is of interest as it appears 
to play both an opposing and complementary role to SphK1 in survival148.  SphK2 is larger 
and has a different amino terminus and central region than SphK1149.    Furthermore, it 
possesses a BH3 like Bcl-2 family binding domain implicated in inducing apoptosis150.  
SphK2b splice variant expression and nuclear translocation is increased in response to 
serum deprivation and causes induction of apoptosis151.  SphK2 is less substrate specific 
than SphK1, phosphorylating substrates other than sphingosine including FTY-720, 
converting this pharmacological agent into a S1P receptor agonist152-154.  Lastly, SphK2 
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overexpression and downregulation results in inhibition of cell growth and induction of 
apoptosis155, 156 .       
 
SphK1 
In contrast to SphK2, SphK1 has been implicated in the pro-survival, proliferative 
effects of S1P that were previously described.  Owing to studies of basal SphK1 activity 
and attenuation of growth response in SphK1 mutants unable to localize to the plasma 
membrane, it seems likely that SphK1 effects are mediated by its membrane localization157, 
158.  Phosphorylation on Ser225 by ERK2 is essential for this membrane affinity159.  This is 
consistent with the observation that sphingosine, SphK1's substrate, resides in the plasma 
membrane. SphK1 is stimulated by a wide variety of plasma membrane receptor ligands, 
particularly growth factors, including platelet-derived growth factor (PDGF)160, vascular 
endothelial growth factor (VEGF)161, epidermal growth factor (EGF)162, and hepatocyte 
growth factor163, as well as cytokines, tumor necrosis factor α164, hormones165, 166, GPCR 
ligands, such as  lysophosphtidic acid 167 and S1P168, as well as other ligands169.  ERK1/2 
phosphorylation by TNFα also appears to require SphK1 activity170.  In addition, SphK1 
directly interacts with TRAF2 (for TNF induced NF-κB activation protecting against 
apoptosis)171, Calcium/calmodulin (which is important for SphK1 agonist induced 
membrane translocation)172, platelet endothelial cell adhesion molecule 1173, delta 
catenin174, aminoacylase175, SphK1 interacting protein176, and RPK118177.  Specific 
knockdown of SphK1 by small interfering RNA triggers apoptosis in multiple tumor cell 
lines178-182.  Effector caspase and cytochrome c release was induced as well as significantly 
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increased levels of ceramide and sphingosine in cells with suppressed SphK1 
expression179.  Thus SphK1 is implicated as a regulatory molecule in the signaling of a 
number of different pro-survival signaling cascades and its knockdown often leads to 
apoptotic cell death. 
 
Sphingolipid metabolism and autophagy 
Elements of the S1P metabolic pathway also have a role in inducing autophagy.  
Increases in ceramide associated with tamoxifen treatment result in accumulation of 
Beclin1, inhibition of Akt phosphorylation and autophagy.  This effect is inhibited by 
pharmacological inhibition of long chain ceramide production by fumonisin B1 and 
replicated by short cell-permeant ceramide183.  In addition, mTORC1 activity is inhibited, 
however in contrast to nutrient starvation, Bcl-2 overexpression does not inhibit 
autophagy183.   
 Interestingly, SphK1 overexpression is also capable of inducing autophagy.  In this 
case, while mTORC1 activity is inhibited, there is little change in beclin1 expression and 
no decrease in Akt phosphorylation.  Nor is the amount of endogenous ceramide shown to 
change. These effects are inhibited by SphK1 RNA interference and the pan SphK 
inhibitor N,N-dimethylsphingosine (DMS) which in turn increases cell death with PARP 
cleavage.  In cells undergoing nutrient starvation, upregulation of SphK1 was also 
observed88. It therefore appears that increases in ceramide result in autophagy associated 
with cell death while SphK1 activation and increased S1P formation may serve to protect 
cells. 
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Pharmacological inhibitors of SphK1 have also been shown to induce autophagy.  
Although not a SphK1 specific inhibitor, Safingol, a synthetic stereoisomer of sphinganine, 
has been shown to inhibit PKC and SphK.  Safingol treatment of  the HCT116 colon 
cancer cell line induces autophagy followed by cell death with concomitant decreases in 
Akt phosphorylation, ERK phosphorylation and mTORC1 activity.  Safingol did not 
however induce increases in ceramide, S1P or dihydroceramide and autophagy induced by 
PKC depletion with siRNA was not of comparable intensity to that induced by Safingol 89. 
Thus, the activity of S1P appears central to cell survival and its biosynthetic pathways 
overlap cell structures sensitive to autophagic induction. 
 
SK1-I 
SK1-I is a water soluble sphingosine analogue shown to competitively inhibit S1P 
production by SphK1 without inhibiting the catalytic activities of SphK2, PKC or a 
number of other protein kinases (Fig 4).  SK1-I decreases growth and survival in human 
leukemia U937 and Jurkat cells and caspase inhibitors and overexpression of Bcl-2 protect 
against apoptosis induced by SK1-I184 . 
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Fig4: Structure of SK1-I 184 
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Statement of Intent 
 Autophagy is the process of “cell self-eating” thought to provide essential nutrients 
to the cell under conditions of nutrient restriction.  Recent observations, however, suggest 
that significantly elevated rates of autophagy induce apoptosis-independent cell death.  
Sphingosine Kinase 1 (SphK1) catalyzes the synthesis of sphingosine 1 phosphate, a 
bioactive lipid signaling molecule which has been shown to suppress apoptosis and 
stimulate cell growth, proliferation and motility. Moreover, it has been shown that SphK1 
induced autophagy protects cells from apoptosis during nutrient starvation88. This study 
seeks to determine whether Sphingosine Kinase 1 Inhibitor (SK1-I), a specific inhibitor of 
SphK1, regulates autophagy, to identify the mechanism of its action, and to evaluate the 
impact of SK1-I induced autophagy on HCT116 colon cancer cell viability. 
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 Materials and Methods 
 
 
Materials 
SK1-I, (2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol 
(BML-258), was synthesized as the HCl salt by BIOMOL International (Plymouth 
Meeting, PA).  Propidium iodide for membrane integrity analysis and bisbenzimide 
Hoechst 33342 for nuclear staining were obtained from Sigma Aldrich (St. Louis, MO).  
LY94002 was obtained from Biomol (Plymouth Meeting, PA).   
 
Cells 
Wild type and p53 null HCT116 human colorectal carcinoma cells were obtained 
from American Type Culture Collection (Manassas, Va).  Cells were cultured and 
maintained in logarithmic growth phase in Dulbecco's Modified Eagle Medium 11995 
containing 4,500 mg/L D-glucose, L-glutamine, and phenol red (DMEM, Invitrogen, 
Carlsbad CA) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad CA).  During 
SK1-I treatment, cells were cultured in DMEM supplemented with 0.1% fatty acid free 
BSA (Sigma Aldrich, St. Louis, MO). 
 
Cell Transfection 
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Cells were plated on poly-L-lysine covered glass coverslips in a 6 well plate at 1 
million cells per well.  After 24 hours, cells were transfected using Lipofectamine 2000 
according to the manufacturer's protocol (Invitrogen, Carlsbad CA).  Cells were transfected 
with pEGFP-C1-rLC3 plasmid (kindly given by T. Yoshimori, National Institute of 
Genetics, Mishima, Japan).  24 hours after transfection, cells were cultured in DMEM 
containing 0.1% BSA and treated with SK1-I as indicated in figure legends.    
 
RNA interference 
Cells were plated on poly-L-lysine covered glass coverslips in a 6 well plate at 
300,000 cells per well.  After 24 hours, cells were transfected using Oligofectamine 
according to the manufacturer's protocol (Invitrogen, Carlsbad CA) with either 100 nM 
Smartpool siRNA for Atg5 (Thermo Scientific Dharmacon, Lafayette, CO) or 100nM 
siRNA for Beclin 1 (Qiagen, Valencia, CA).  Cells were transfected with pEGFP-C1-rLC3 
24 hours after siRNA transfection using Lipofectamine 2000.  24 hours later, cells were 
then cultured in DMEM containing 0.1% BSA and treated with SK1-I as indicated in 
figure legends.    
 
Confocal Microscopy 
Cells grown on glass cover slips were fixed using 3.7% paraformaldehyde (Sigma 
Aldrich, St. Louis, MO) in phosphate buffered saline.  Cover slips were mounted using 10 
nM N-propyl gallate (Sigma Aldrich, St. Louis, MO).  Images were acquired with a Zeiss 
LSM 510 confocal microscope with a 63x objective lens.  Excitation (ex.) and emission 
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(em.) filter settings were:  GFP ex. 488 nm, em. long pass 505. The number of GFP-LC3 
positive cells with more than 5 GFP-LC3 dots was determined. Quantification was 
performed by Dr. Sandrine Lépine. 
 
Western blot analysis 
Adherent and detached cells were collected and resuspended in cell lysis buffer (20 
mM Tris (pH 7.5), 150 mM NaCl, 1mM EDTA, 2.5 mM sodium pyrophosphate, 1mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1%Triton X-100, Sigma protease inhibitor 
cocktail).  Lysates were sonicated and centrifuged. After protein quantification (Bio-Rad, 
Hercules, CA), equal amounts of protein were separated by 10% sodium dodecyl sulfide–
polyacrylamide gel electrophoresis (SDS-PAGE) and then transblotted to nitrocellulose. 
Blots were incubated with primary antibodies overnight in Tris-buffered saline (TBS) 
containing 3%BSA.  
 The following were used as primary antibodies at 1:1000 dilution (except in the 
case of Phospho-Akt, 1:500): Phospho-Akt(Ser473) (rabbit polyclonal), Akt (rabbit 
polyclonal), Phospho-mTOR(Ser2448)(rabbit polyclonal), mTOR (rabbit polyclonal), 
Phospho-Erk1/2 (Thr202/Tyr204) (rabbit polyclonal), Erk2(rabbit polyclonal), Phospho-
eIF2α (Ser 51) (rabbit polyclonal), Clathrin Heavy Chain (rabbit polyclonal) (Cell 
Signaling, Beverly, MA), Beclin (mouse polyclonal) (BD Pharmingen, San Diego, CA), 
and anti-PARP (rabbit polyclonal) (BIOMOL International), APG5L (rabbit polyclonal) 
(Abgent, San Diego, California), LC3 (rabbit polyclonal) (Novus Biologicals, Littleton, 
CO). 
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 After washing, cells were incubated for one hour at room temperature with 
peroxidase conjugated anti–rabbit or anti-mouse IgG (1:10 000; Jackson Immunoresearch 
Laboratories, West Grove, PA). Immunocomplexes were visualized using Super Signal 
West substrate (Thermo Fisher Scientific, Rockford, Illinois) with Kodak (Rochester, NY) 
or Phenix Research Products (Candler, NC) X-ray film. 
 
Cell Death Assay 
 Cells were plated at four hundred thousand cells per well in a 6 well plate.  Cells 
were given 24 hours to adhere.  Cells were then cultured in DMEM containing 0.1% BSA 
in the absence or presence of 10 μM SK1-I for 24 hours. Apoptotic and necrotic cells were 
quantified by fluorescence microscopy after labeling with Hoescht 33342 (10  µg/ml) and 
propidium iodide (50µg/ml). Cells were visualized with a Nikon eclipse TE300 
fluorescence microscope. Cells exhibiting blue condensed or fragmented nuclei or red 
condensed nuclei were considered apoptotic. Red nuclei without signs of condensation or 
fragmentation were considered necrotic. 
 
Statistical Analysis 
 For each experiment, data from samples were calculated and expressed as the mean 
plus or minus standard deviation (SD). The significance of differences between 
experimental conditions was determined using the Student t test for unpaired observations.  
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 Results 
 
 
SK1-I Induces autophagy in a time and dose dependent manner 
Previous studies have shown that upregulation of SphK1 expression associated with 
increases in S1P result in increased autophagic vesicle formation88.  As such, it was of 
interest to investigate the effect on autophagy of the isotype specific sphingosine kinase 1 
inhibitor, SK1-I184 .   
In this study we used HCT116 wild type p53 and p53 null cells as our model 
system.  First we verified that p53 null cells did not express p53.  This was demonstrated 
by western blot (Fig 5A) of p53. 
In order to visualize autophagosome accumulation, we observed changes in 
localization and lipidation of LC3, a protein whose attachment to the isolation membrane 
(unenclosed autophagosomal precursor) is considered necessary for autophagosome 
formation51.  Shortly after translation, LC3’s carboxy terminal region is cleaved creating 
LC3I.  Upon induction of autophagy, LC3I is lipidated with phosphatidylethanolamine 
forming LC3II.  LC3II specifically localizes to the developing autophagosome membrane 
51,185.  GFP-LC3 also undergoes this process thereby labeling autophagosomal structures 
with GFP in a manner consistent with direct immunohistochemical staining185.  Thus, in 
order to determine whether SK1-I induces autophagosome formation, we transfected 
HCT116 colon cancer cells with a plasmid expressing GFP conjugated LC3 and autophagy 
was quantified using confocal microscopy.  In vehicle treated cells in which no autophagy 
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was induced, GFP staining appeared as a diffuse light green fluorescence present in the 
cytosol.  In cells with autophagy, GFP fluorescence appeared as concentrated green puncta. 
One limitation of this method is that GFP-LC3 is prone to form aggregates which resemble 
GFP-LC3II puncta186.  Furthermore, cells are expected to engage in some basal level of 
autophagy.  Therefore, we quantified the number of cells with more than GFP-LC3 puncta 
in a double blind manner. We observed that SK1-I induced an elevated level of autophagic 
vesicle formation in a time and dose dependent manner (Fig. 5).  Because p53 has been 
shown to be involved in autophagy187, we examined whether the effect of SK1-I on 
autophagy was influenced by the presence of p53 expression. Both wild-type and p53 null 
HCT116 cells had significant levels of autophagy within 3 hours of exposure to 10μM 
SK1-I (Fig 5b).  35 percent of cells expressing wild type p53 and 32 percent of p53 null 
cells were autophagic.  Wild type cells continued to become increasingly autophagic until 
approximately 24 hours at which time 67 percent were autophagic and rates leveled off.  
p53 null cells became increasingly autophagic until 12 hours at which time approximately 
40 percent of cells exhibited maximal autophagy (Fig. 5b).  Similarly, significant increases 
in response to SK1-I concentration were observed in both wild type and p53 null cells 
when cultured in 10μM SK1-I for 6 hours as compared to cells cultured at 3 or 5μM SK1-I 
(Fig 5c).  At 10μM SK1-I, 41 percent of wt cells and 23 percent of p53 null cells were 
autophagic.  Thus there was a significantly higher percentage of punctate staining in wild 
type cells than in p53 null cells in response to SK1-I treatment (Fig. 5).   
SK1-I induction of autophagy was confirmed using western blot (Fig 6).  As a 
result of its lipidation, LC3II has greater mobility than LC3I in SDS-PAGE185.  Increases 
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in LC3 lipidation and thus accumulation of autophagosomes can therefore be evaluated 
based on the differential induction of LC3I and LC3II in response to treatment.  LC3 
lipidation increased as a function of SK1-I time and dose as seen by an increase in LC3II 
intensity relative to LC3I (Fig. 6).  Interestingly, in SK1-I treated cells, earliest increases in 
lipidation were observed at 15 minutes (Fig. 6a).  The lowest concentration at which SK1-I 
elicited a response appeared to be 10μM (Fig. 6b).  As such, 10μM SK1-I was used for all 
other experiments. 
 
SK1-I does not trigger classical Beclin 1 or mTORC1 signaling  
Increases in Beclin1 protein have commonly been associated with autophagy 
induction27, 42, 183.  We therefore examined changes in Beclin1 protein expression during 
the three hour period in which autophagy was seen to be initiated.  Western blot of whole 
cell lysates showed that Beclin 1 protein levels were not upregulated in HCT116 wt or 
p53-/- cells after exposure to SK1-I (Fig. 7 A, B).  Previous studies have also shown that in 
cases in which Beclin1 protein levels do not change, interactions with other protein factors 
mediate autophagic induction in a Beclin1 dependent fashion (UVRAG65, Ambra66,       
Bcl-267).  To eliminate this possibility, Beclin1 protein expression was downregulated 
using short interfering RNA for Beclin1.  The efficiency of Beclin 1 downregulation was 
confirmed by western blotting for Beclin1 protein (Fig 8).  Examination of LC3 lipidation 
by western blot revealed that downregulation of Beclin 1 did not attenuate induction of 
autophagy with SK1-I (Fig. 8).  Beclin1 and its interactions with other regulatory proteins 
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(i.e. UVRAG, Ambra, or Bcl-2) was therefore considered unlikely to mediate autophagy 
induction by SK1-I.   
Next, the role of rapamycin sensitive mTOR complex (mTORC1) was considered.  
mTORC1 integrates numerous growth factor and nutrient signaling pathways and regulates 
the transcriptional response to these pathways188.  Most commonly, mTORC1 is 
considered to be downstream of Akt and ERK 75, 76, 189 although the exact mechanism of its 
activation is unclear.  In mammalian cells, inhibition of mTORC1 is sufficient to induce 
autophagy and is required for autophagy due to nutrient starvation84-86 .   
 Changes in mTORC1 activity were evaluated by blotting for Phospho-
mTOR(Ser2448).  During the first three hours of SK1-I treatment (when there is a 
significant increase in autophagy), mTOR phosphorylation was not seen to be reduced 
relative to control (Fig. 9).  We therefore conclude that there is no significant change in 
mTORC1 activity in response to SK1-I treatment.  
  
Non-canonical mTORC2 signaling is observed 
The downstream signaling of the rapamycin insensitive mTOR complex 
(mTORC2) was then examined.  mTORC2 downregulation was shown to induce FoxO3 
nuclear translocation in transfected myofibers, which correlated with expression of 
autophagy inducer BNIP protein.  A resulting increase in autophagosome formation was 
observed independent of mTORC1 inhibition99. 
mTORC2 has been identified as the primary complex to phosphorylate Akt on 
Ser47395.  Phosphorylation of Akt ser473 was evaluated by western blot as a downstream 
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target of mTORC2 activity.  It was observed that phosphorylation of Akt at Serine 473 was 
consistently lower in SK1-I treated cells than in vehicle treated cells (Fig. 10a).   
Furthermore, induction of LC3 lipidation was observed at the same time point as this 
decrease in Akt phosphorylation (Fig. 10b).   
 
Akt is not involved in autophagy 
In order to investigate the effects of potential Akt inhibition on autophagy 
induction, cells were treated with LY294002 a specific inhibitor of type1 PI3kinase 190 to 
inhibit Akt phosphorylation.  Akt (Ser 473) and downstream target mTOR(Ser2448) 
phosphorylation were examined.  LY294002 resulted in more intense reductions in Akt 
and mTOR phosphorylation than did SK1-I (Fig. 11).  Even so, autophagic response to 
SK1-I treatment was observed to be much stronger than that induced by inhibition of Akt 
phosphorylation and mTORC1 inactivation (Fig. 11).  An additive effect by LY294002 
and SK1-I treatment on LC3 lipidation was observed.  Taken together, this data suggests 
that inhibition of phosphorylation of Akt may not be a major contributor to SK1-I induced 
autophagy.  
 
SK1-I induced ER stress 
ER stress and the unfolded protein response (UPR) have been implicated in 
autophagy109.  Furthermore, the UPR does not require Beclin1 for activation191.  During 
ER stress, protein kinase r-like ER kinase (PERK) is activated in response to decreases in 
calcium or protein misfolding.  In turn it phosphorylates transcription factor eIF2alpha107, 
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192.  eIF2alpha phosphorylation is also necessary for Atg 12 mediated LC3 conversion 
during autophagy due to aggregation of polyglutamine repeat proteins in the ER102.  
EIF2alpha phosphorylation was examined by Western blot.  eIF2alpha showed 
significantly elevated levels of phosphorylation in comparison with untreated cells 
beginning within 15 minutes of treatment with SK1-I (Fig. 12), similar to the time course 
observed in LC3 lipidation (Fig 2a).  In addition, eIF2alpha phosphorylation was seen to 
increase in response to 6 hours treatment with 10μM SK1-I rather than 5μM SK1-I, just as 
was observed for LC3II appearance (Fig. 6b).  These results indicate that SK1-I induces 
ER stress that could be responsible for SK1-I induced autophagy. 
 
Atg5 is necessary for SK1-I autophagic induction 
To determine whether other elements of the canonical autophagy induction 
pathway were necessary for accumulation of LC3 associated vesicles in SK1-I treated 
cells, small interfering RNA for Atg5 was used.  Atg5 has been shown to localize to the 
isolation membrane and be necessary for autophagosome formation25.  Small interfering 
RNA for Atg5 inhibited induction of autophagy as measured by LC3 lipidation (Fig. 8).  
This confirmed that LC3 lipidation was dependent upon Atg5, a known participant in 
autophagic vesicle nucleation. 
 
SK1-I induces non-apoptotic cell death in wild type HCT116 cells and apoptosis in 
p53 null cells 
   
48 
 
Cell survival in response to SK1-I was then examined.  Propidium Iodide staining 
in combination with Hoechst 33342 has been shown an effective method of visualizing 
membrane permeablization, and nuclear condensation, respectively193.  Nuclear 
condensation is considered a cytological marker of apoptosis193.  Membrane 
permeablization without nuclear condensation is considered to indicate non-apoptotic cell 
death193.  By propidium iodide staining, 94 percent of wild type cells cultured in 10μM 
SK1-I for 24 hours were observed to be membrane permeablized without nuclear 
condensation (Fig. 13).  P53 null HCT116 cells treated with SK1-I were observed to have a 
higher percentage of apoptosis (35 percent) than control (3 percent) or wild type  cells (3 
percent), with insignificant amounts of membrane permeablization (Fig. 13).  While p53 
null cells underwent apoptosis, wild type cells appeared highly susceptible to a non-
apoptotic form of cell death.   
To confirm the observation of non-apoptotic cell death in wild type HCT116 cells, 
Poly-(ADP-ribose) polymerase (PARP) cleavage was evaluated by western blot.  PARP is 
a nuclear protein implicated in DNA repair.  PARP is one of the earliest proteins targeted 
for specific caspase cleavage and the best characterized caspase substrate in measuring 
apoptotic cell death194.  No PARP cleavage was detected in wild type HCT116 cells up to 
24 hours (Fig. 14) indicating that the permeablization observed in these cells is not a result 
of apoptotic cell death.  ERK phosphorylation was also observed as an indicator of cell 
survival.  ERK phosphorylation was reduced in both wild type and p53 null cells (Fig. 15), 
suggesting that this does not contribute to the distinct apoptotic responses of p53 null 
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HCT116. Altogether these results demonstrate that SK1-I induced a non-apoptotic cell 
death in HCT116 wt cells while inducing apoptosis in HCT116 p53 null cells. 
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Figure 5.  SK1-I Induces autophagy with different intensity in human wild type p53 
expressing HCT116 colon carcinoma cells, and in their p53-null counterparts.  
A. Equal amounts of lysate proteins from naive wild type and p53 null HCT116 cells were resolved 
by SDS-PAGE and analyzed by western blotting with antibodies against p53.  Blots were stripped 
and reprobed for βTubulin to demonstrate equal loading and transfer.  B-D. LC3-GFP transfected 
wild type and p53null HCT116 cells cultured in DMEM supplemented with 0.1%BSA were treated 
with 10μM SK1-I in for the indicated time (B,C) or with the indicated concentrations of SK1-I for 
6 hours (D). Cells were examined by confocal fluorescence microscopy. (B) Representative images 
are shown. Scale bars, 10 µm. (B) Percentage of cells showing GFP-LC3 fluorescence in puncta 
was quantified. Data are means ± SD.
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Figure 6:  SK1-I induces LC3 lipidation in HCT116 cells.   
A,B. Naive HCT116 cells cultured in DMEM supplemented with 0.1%BSA were treated 
without or with 10μM SK1-I  for the indicated times (A) or with the indicated 
concentrations of SK1-I for 6 or 24 hours (B). HCT116 cells were also cultured with 
2%FCS for 6 hours and 24 hours as a control. Equal amounts of lysate proteins were 
resolved by SDS-PAGE and analyzed by western blotting with antibodies against LC3.  
Blots were stripped and reprobed for total Akt, Clathrin Heavy Chain, or βTubulin to 
demonstrate equal loading. 
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Figure 7:  SK1-I induces autophagy without increasing Beclin1. 
Wild type (A) and p53 null (B) HCT116 cells cultured in DMEM supplemented with 
0.1%BSA were treated without or with 10μM SK1-I for the indicated times.  Equal 
amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western blotting 
with antibodies against Beclin1.  Blots were stripped and reprobed for βTubulin to 
demonstrate equal loading. 
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Figure 8: Atg5 but not Beclin1 is required for SK1-I-induced autophagosome 
formation.     
HCT116 wt cells were transfected with siControl, siBeclin or siATG5 then transfected 
with LC3-GFP.  Cells were cultured for 24 hours then treated with without or with the 
indicated concentrations of SK1-I in DMEM supplemented with 0.1%BSA for 6 hours.  
Equal amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western 
blotting with antibodies against LC3.  Blots were stripped and reprobed for Beclin1 to 
ensure protein expression knockdown.  Blots were stripped and reprobed for Clathrin 
Heavy Chain to demonstrate equal loading.
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Figure 9: SK1-I does not inactivate mTOR complex 1. 
Wild type and p53 null HCT116 cells cultured in DMEM supplemented with 0.1%BSA 
were treated without or with 10μM SK1-I for the indicated times.  Equal amounts of lysate 
proteins were resolved by SDS-PAGE and analyzed by western blotting with antibodies 
against Phospho-mTOR(Ser2448).  Blots were stripped and reprobed for mTOR for 
comparison with phosphorylation.  Blots were stripped and reprobed for Erk2 to 
demonstrate equal loading. 
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Figure 10: SK1-I treatment decreased phosphorylation of Akt concomitantly with 
LC3 lipidation. 
Wild type and p53 null HCT116 cells were treated without (-) or with 10μM SK1-I (+) for 
the indicated times. Equal amounts of lysate proteins were resolved by SDS-PAGE and 
analyzed by western blotting with antibodies against Phospho-Akt (Ser473) (A and B).  
Blots were stripped and reprobed for Erk2 (A) or total Akt (B) to demonstrate equal 
loading. 
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Figure 11:  SK1-I induces autophagy independently of Akt and mTORC1    
CT116 cells cultured in DMEM supplemented with 0.1%BSA were treated with 10μM 
LY294002 or 10μM SK1-I or a combination of both for 30 minutes.  Equal amounts of 
lysate proteins were resolved by SDS-PAGE and analyzed by western blotting with 
antibodies against Phospho-mTOR(Ser2448), LC3 and Phospho-Akt. Blot was stripped 
and reprobed for Clathrin Heavy Chain to demonstrate equal loading. 
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Figure 12:  SK1-I treatment induces ER stress 
Wild type and p53 null HCT116 cells cultured in DMEM containing 0.1% BSA were 
treated without (-) or with 10μM SK1-I (+) for the indicated times (A) or with the indicated 
concentration of SK1-I for 6 hours and 24 hours (B). Equal amounts of lysate proteins 
were resolved by SDS-PAGE and analyzed by western blotting with antibodies against 
Phospho-eIF2α (A) or Phospho-eIF2α and LC3 (B).   Blots were stripped and reprobed for 
Erk2 (A) or βTubulin (B) to demonstrate equal loading.
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A.                                     Apoptosis 
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Figure 13 
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C.                                untreated HCT116 wt (Hoechst Blue, PI red) 
 
 
 
 
SK1-I HCT116 wt (Hoechst Blue, PI red) 
 
 
 
 
 
 
 
Figure 13:  SK1-I induces non-autophagic death in wild type HCT116 cells and 
apoptosis in p53-/-  HCT116 cells. 
Wild type and p53 null HCT116 cells were treated with 10μM SK1-I for 24 hours.  Cells 
were fixed and stained with propidium iodide and Hoechst and percentage of cells with 
permeablized membranes (A) or condensed nuclei (B), respectively, were counted. C. 
representative field of untreated wild type HCT116 cells (top) or 10μM SK1-I treated for 
24 hours (bottom).  
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Figure 14:  SK1-I did not induce PARP cleavage in wt cells. 
HCT116 cells were treated without (-) or with 10μM SK1-I (+) for the indicated times. 
Equal amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western 
blotting with antibodies against PARP.  Blots were stripped and reprobed for Clathrin 
Heavy Chain to demonstrate equal loading. 
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Figure 15:  SK1-I decreases ERK1/2 phosphorylation 
Wild type and p53 null HCT116 cells were treated without (-) or with 10μM SK1-I (+) for 
the indicated times. Equal amounts of lysate proteins were resolved by SDS-PAGE and 
analyzed by western blotting with antibodies against Phospho-Erk1/2.  Blots were stripped 
and reprobed for Erk2 to demonstrate equal loading. 
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 Discussion 
 
 
Autophagy Induction by SK1-I: an Unexpected Result 
Autophagy has traditionally been associated with the adaptive responses of nutrient 
deprived cells.  This nutrient response was primarily associated with increased Beclin 1 
activity and decreased mTORC1 activity84-86.  Recently, however, autophagy has been 
associated with maintaining cell homeostasis and in some cases contributing to cell 
death22.  This study places the effects of the isotype SphK1 inhibitor SK1-I within this new 
paradigm and investigates its mechanism of action.  In many respects, the findings of this 
study differ significantly from the previously reported observations of autophagy induced 
by SphK1 upregulation 88 and ceramide increase183, suggesting a novel mechanism of 
autophagy induction. 
SK1-I treatment increased autophagy significantly in cells expressing or lacking 
p53.  This increase in autophagy was unusual in three aspects.  Firstly, very rapid induction 
of autophagy was observed.  By western blotting to examine LC3 lipidation, it was 
possible to observe LC3 conversion in response to SK1-I treatment within 15 minutes.  
This finding was difficult to compare with previous investigations of autophagy as they 
often only evaluated autophagy after longer periods of time.  Nevertheless, Tasdemir et al. 
2008195 , showed that in HCT116 cells wild type for p53, lithium (IP3R antagonist), 
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tunicamycin, rapamycin or ABT737 (Bcl-2 inhibitor, BH3 mimetic small molecule) 
typically required more than 1 hour to demonstrate changes in LC3 lipidation195.  In other 
experiments, ligand induced JNK activation 196 or IP3R antagonism 91 was observed to 
require 12 hours of treatment for autophagy induction. Other studies evaluating 
sphingolipid metabolites such as that investigating 100 µM C2-Cer induced autophagy and 
nutrient starvation, only evaluate autophagy after 4 hours of treatment69. 
Secondly, autophagy was induced more profoundly in cells expressing wild type 
p53 than in cells which p53 was absent.  Tasdemir et al 195 have proposed that cytoplasmic 
p53 is degraded during the autophagic process.  In HCT116 cells, it was observed that 
cytosolic p53 inhibition, depletion or deletion causes a maximal level of autophagy that 
cannot be enhanced by chemical agents used to trigger nutrient deprivation or ER stress 195.  
Furthermore, induction of autophagy by these agents can be inhibited by preventing the 
degradation of p53.  This inductive effect is, however, cell cycle dependent and only 
causes autophagy in G1or S phase.  In contrast, nuclear p53 is known to promote 
transcription of pro-autophagy factors such as the DAPK proteins197.  It is difficult, 
therefore to implicate p53 directly in this differential induction of autophagy except 
perhaps as regulator of the cell cycle, allowing cells to spend more time in highly 
autophagic G1 or S phase, and as potential transcription factor.  It was, however, noted (as 
seen in differential phosphorylation levels of eIF2α, mTOR, Akt and ERK proteins and 
unreported blotting of EGF receptor phosphorylation), that wild type p53 and p53 null 
cells displayed significant differences in the basal status of signaling pathways normally 
associated with autophagy.  These differences, which may or may not be directly 
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associated with p53 status, may also account for some difference in autophagy intensity 
induced by SK1-I.  
Lastly, inhibition of SphK1 using RNA interference or DMS in MCF7 breast 
cancer cells was previously reported to attenuate the autophagic response induced by 
nutrient starvation or SphK1 upregulation88.  Our observation of a rapid increase in 
autophagy using SK1-I is quite distinct from this earlier report.  However, observations by 
Coward et al (2009) that safingol, an unspecific SphK and PKC inhibitor, induces 
autophagy more strongly than can be accounted for by PKC inhibition alone, and without 
concomitant increases in sphingosine, S1P, or ceramide metabolites89, lead one to wonder 
what effects SK1-I has on sphingolipid metabolite levels at early time points and whether 
its accumulation or modification may account for its effects (it could, for example, it be  N-
acylated to become a dihydroceramide analogue as does safingol 198 and induce autophagy 
through a similar mechanism as resveratrol which shares beclin1 independent 
characteristics.  In addition, the anti ceramide-tunnel forming characteristics of 
dihydroceramide would help to account for the lack of apoptosis in wild type cells199).  
Interestingly, SK1-I also induced rapid autophagy in glioblastoma cells (D. Kapitonov, 
unpublished) and SK1-I treatment induced a very rapid decrease in S1P (within 20 
minutes). This was followed by an increase in sphingosine at 1 hour and a later increase in 
ceramide (D. Kapitonov et al, submitted to Cancer Research). Therefore, the potent effect 
on autophagy of SK1-I could be due to a lack of intracellular S1P or increases in 
sphingosine and ceramide.  In order to investigate this possibility in HCT116 cells, mass-
spectophotometric analysis of cells treated with SK1-I at early time points should be 
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performed examining SK1-I and sphingolipid metabolites.  In turn, detected differences in 
quantity and structure of these metabolites should be introduced as alternative treatment 
conditions and compared with the SK1-I effect.  
 
Absence of Beclin1 or mTORC1 effects offer mechanistic insights 
Although Beclin 1 is considered to have a significant role in regulating autophagy, 
no such involvement was observed with SK1-I.  Previously, genetic upregulation of Beclin 
levels have been shown to induce autophagy27.  Futhermore, in response to ceramide, a 
robust increase in Beclin1 has been observed183.  Even without changes in Beclin 
expression, starvation induced autophagy is inhibited by Bcl-2 binding to Beclin 67 and 
Bcl-2 binding is regulated by its ceramide dependent phosphorylation69.  Ambra and 
UVRAG also regulate autophagy by mediating the interaction between Beclin 1 and 
Vps3465, 66.  The observed down regulation of total Beclin1 expression in this study, 
without significant inhibition of autophagy, however, suggests that these Beclin 1 
regulatory mechanisms do not have a significant role in the SK1-I induced autophagic 
effect.  While not conclusive, these results also cast doubt on the possibility that ceramide 
may be the primary cause of SK1-I induced autophagy.  This further emphasizes the need 
for investigation of SK1-I induced changes in sphingolipid metabolism during early SK1-I 
treatment.  Furthermore, it may be of interest to compare the effects of Resveratrol, which 
induces a Beclin 1 independent, dihydroceramide mediated, form of autophagy70,135, with 
those of SK1-I. 
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Inhibition of mTORC1 is also commonly observed with induction of autophagy, 
and yet was not observed in SK1-I treated cells.  In mammalian cells, inhibition of 
mTORC1 is sufficient to induce autophagy and is required for autophagy due to nutrient 
starvation84-86.  Elevated mTORC1 activity results in cells with impaired ability to initiate 
autophagy in response to nutrient starvation85.  Reduced mTORC1 activity has been 
observed in autophagic cells as a result of ER stress associated with Ca activated AMPK 
signaling68, elevated SphK1 expression88, elevated ceramide levels69, and treatment with 
Safingol89.  Our results are consistent with the notion that autophagy is not being induced 
by a nutrient starvation pathway.  We also observed that Akt activity and downstream 
signaling through mTORC1 does not account for autophagy induced by SK1-I.  Complete 
downregulation of Akt phosphorylation and downstream decrease in mTOR 
phosphorylation resulted in little increase in LC3 lipidation while SK1-I treatment, with 
comparatively much less inhibition of Akt and mTOR phosphorylation , resulted in a much 
higher rate of LC3 lipidation.  Furthermore, treatment with both the Akt inhibitor and SK1-
I appeared to produce an additive effect on LC3 lipidation.  Owing to Akt's importance in 
S1P receptor signaling, this may support the possibility of an intracellular mechanism of 
action. 
  Interestingly, changes in mTORC1 activity have not been observed in autophagy 
induced by PKCθ in response to calcium90, or IP3R in response to reduction in IP3R 
expression91.  Therefore, further investigation of these ER associated mechanisms of 
autophagy may provide some insight into the mechanism of SK1-I induced autophagy.   
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Translational effects, cytoskeletal changes, and a role for the ER 
 Ultimately, inhibition of autophagy by knockdown of Atg5 confirmed that SK1-I 
effects were dependent upon the conserved mechanism of initial autophagosome 
formation. Therefore, investigation of other, less conventional autophagic pathways 
seemed warranted.  The observation that Akt serine 473 dephosphorylation and eIF2α 
phosphorylation occur concomitantly with the first observed increase in LC3 lipidation 
suggest a role for mTORC2 and ER stress in mediating autophagy induced by SK1-I. 
 mTORC2 is of particular interest in SK1-I induced autophagy because it is 
considered to play a role in regulation of the actin cytoskeleton 97 much as has SphK1200.  
In addition, growth factor independent mTORC2 activity has been shown to be necessary 
for carboxyl-terminal folding and stabilization of newly synthesized Akt and PKC96.  
mTORC2 downregulation has been shown to induce FoxO3 nuclear translocation in 
transfected myofibers, which correlates with expression of autophagy inducer BNIP 
protein.  Autophagosome formation is observed in response to mTORC2 inhibition without 
mTORC199.  Changes in cytoskeletal  organization, inhibition of protein synthesis and 
autophagic protein expression could all contribute to an autophagic effect.  Therefore, 
further investigation of co-localization, constituitive activation and downregulation of 
mTORC2's binding constituents in relation to SphK1 may shed light on a new intracellular 
mechanism of SphK1 action.  
 In response to perturbations in protein folding/glycosylation, shuttling of proteins 
to the Golgi, ER calcium balance, and synthesis of fatty acids, sterols and phospholipids, 
ER stress is induced19.  Each of these perturbations may also induce autophagy109.  There is 
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some evidence that calcium release from the ER is the primary signal initiating the ER 
mediated autophagic response109.  ER stress results in eIF2α phosphorylation192.  
Furthermore, eIF2α phosphorylation has been shown necessary for LC3 conversion by 
induction of Atg12 during ER stress caused by aggregation of polyglutamine repeat 
proteins102.   Based on the finding that eIF2α is phosphorylated in response to SK1-I 
treatment, ER stress due to protein misfolding and modification,  ER integrity, lipid 
synthesis and trafficking, and calcium homeostasis should be further investigated as 
mediators of SK1-I autophagy.  Furthermore, treatment of HCT116 cells with non-specific 
SphK inhibitor N,N-dimethyl-D-erythro-sphingosine (DMS) a sphingosine analogue, has 
been shown to induce cytosolic calcium release by an IP3R independent mechanism201.   
As such, one first step in this process is to confirm that cytosolic calcium chelation cannot 
inhibit autophagy and that signaling through a known ER stress sensor is necessary for 
SK1-I induced autophagy as would be demonstrated by sensor knockdown102, 110.   
Furthermore, because the mitochondria are in such close apposition to the ER, and the ER 
plays a role in mitochondrial homeostasis, mitochondrial changes may also be considered.  
 
Autophagic Death? Need for Further Investigation of the Mechanisms of Death  
Lastly, SK1-I causes non-apoptotic and apoptotic death including reductions in Akt 
and ERK phosphorylation.  In addition, death was induced differentially in wt and p53 null 
cells.  This may be accounted for by the intensity of autophagy induction in each cell type 
and other observed differences between wt and p53 null cells.  However, to determine the 
relationship between autophagy, apoptosis, and cell death, inhibition of autophagy using 
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siAtg5 and observations of the resulting cell viability and death signaling may be 
worthwhile. 
In sum, SK1-I rapidly induces autophagy with non-canonical signaling involving 
decreased mTORC2 activity and ER stress.  The result is cell death whose differential 
expression in wild type p53 and p53 null cell lines parallels their differences in autophagic 
intensity.  The relationship of these observations to sphingolipid metabolism and putative 
changes in ER homeostasis or mTORC2 activity warrants further investigation as does the 
clinical utility of SK1-I in the treatment of cancer or other conditions in which cytotoxicity 
or autophagy may have therapeutic value. 
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Figure 16: Schema of Autophagy induced by SK1-I 
 
 
 
SK1-I
SphK1
S1Pceramide sphingosine
ER 
Stress 
ER 
Stress
Autophagy
mTORC2
   
71 
 
 
 
 
 Literature Cited 
   
72 
 
 
 
Literature Cited 
 
1. Cuervo A. Autophagy: Many paths to the same end. Mol Cell Biochem. 2004;263:55. 
2. Klionsky , Yorimitsu . Autophagy: Molecular machinery for self-eating. Cell Death 
Differ. 2005;12 Suppl 2:1542. 
3. Glaumann , Marzella , Ahlberg . Uptake and degradation of proteins by isolated rat liver 
lysosomes. suggestion of a microautophagic pathway of proteolysis. Laboratory 
Investigation. 1982;47:523. 
4. Glaumann . Crinophagy as a means for degrading excess secretory proteins in rat liver. 
Revisiones sobre biología celular. 1989;20:97. 
5. Dice , Cuervo . A receptor for the selective uptake and degradation of proteins by 
lysosomes. Science. 1996;273:501. 
6. Trump , Arstila . Studies on cellular autophagocytosis. the formation of autophagic 
vacuoles in the liver after glucagon administration. The American Journal of Pathology. 
1968;53:687. 
7. Klionsky D, Mizushima N. Protein turnover via autophagy: Implications for 
metabolism. Annu Rev Nutr. 2007;27:19. 
8. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell 
survival in the absence of apoptosis. Cell. 2005;120:237-248. 
   
73 
 
9. Mortimore , Lardeux . Amino acid and hormonal control of macromolecular turnover in 
perfused rat liver. evidence for selective autophagy. The Journal of biological chemistry. 
1987;262:14514. 
10. Rami . Autophagy in neurodegeneration: Fire-fighter and/or incendiarist? Neuropathol 
Appl Neurobiol. 2009. 
11. Klionsky D, Levine B. Development by self-digestion: Molecular mechanisms and 
biological functions of autophagy. Developmental cell. 2004;6:463. 
12. Blum J, Crotzer V. Autophagy and its role in MHC-mediated antigen presentation. The 
journal of immunology. 2009;182:3335. 
13. Codogno P, Pierron G, Souqure S, et al. NF-kappaB activation represses tumor 
necrosis factor-alpha-induced autophagy. The Journal of biological chemistry. 
2006;281:30373. 
14. Elazar Z, Scherz-Shouval R. ROS, mitochondria and the regulation of autophagy. 
Trends Cell Biol. 2007;17:422. 
15. Bassham D, Contento A, Xiong Y. Disruption of autophagy results in constitutive 
oxidative stress in arabidopsis. Autophagy. 2007;3:257. 
16. Kominami E, Tanaka K, Chiba T, et al. Excess peroxisomes are degraded by 
autophagic machinery in mammals. The Journal of biological chemistry. 2006;281:4035. 
17. Levine B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular 
defense. Cell. 2005;120:159. 
18. Andersen J, Kristensen A, Dengjel J. Ordered bulk degradation via autophagy. 
Autophagy. 2008;4:1057. 
   
74 
 
19. Schrder . Endoplasmic reticulum stress responses. Cellular and molecular life sciences. 
2008;65:862. 
20. Kroemer G, Geneste O, Hickman J, et al. BH3-only proteins and BH3 mimetics induce 
autophagy by competitively disrupting the interaction between beclin 1 and bcl-2/Bcl-
X(L). Autophagy. 2007;3:374. 
21. Kroemer , Lavandero , Szabadkai , et al. The inositol 1,4,5-trisphosphate receptor 
regulates autophagy through its interaction with beclin 1. Cell Death Differ. 2009;16:1006. 
22. Tsujimoto Y, Thompson C, Arakawa-Kobayashi S, et al. Role of bcl-2 family proteins 
in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 
2004;6:1221. 
23. Marx J. Autophagy: Is it cancer's friend or foe? Science. 2006;312:1160. 
24. Kondo S, Sawaya R, Kanzawa T, Kondo Y. The role of autophagy in cancer 
development and response to therapy. Nature Reviews.Cancer. 2005;5:726. 
25. Yoshimori , Ohsumi , Tokuhisa , et al. Dissection of autophagosome formation using 
Apg5-deficient mouse embryonic stem cells. J Cell Biol. 2001;152:657. 
26. Yoshimori , Ohsumi , Kominami , et al. LC3, a mammalian homologue of yeast 
Apg8p, is localized in autophagosome membranes after processing. EMBO J. 
2000;19:5720. 
27. Levine , Hibshoosh , Kempkes , et al. Induction of autophagy and inhibition of 
tumorigenesis by beclin 1. Nature. 1999;402:672. 
28. Saftig , von Figura , Blanz , et al. Accumulation of autophagic vacuoles and 
cardiomyopathy in LAMP-2-deficient mice. Nature. 2000;406:902. 
   
75 
 
29. Saftig P, Von Figura K, Blanz J, et al. Role of LAMP-2 in lysosome biogenesis and 
autophagy. Mol Biol Cell. 2002;13:3355. 
30. Lucocq J, Backer J, Tang X, et al. Inhibition of autophagy in mitotic animal cells. 
Traffic. 2002;3:878. 
31. Eskelinen E. Maturation of autophagic vacuoles in mammalian cells. Autophagy. 
2005;1:1. 
32. Bellen H, Pennetta G, Zhou , Wu M, Atkinson R, Lloyd T. Hrs regulates endosome 
membrane invagination and tyrosine kinase receptor signaling in drosophila. Cell. 
2002;108:261. 
33. Sugamura K, Shimosegawa T, Ueno Y, et al. Role of hrs in maturation of 
autophagosomes in mammalian cells. Biochem Biophys Res Commun. 2007;360:721. 
34. Yoshimori T, Ohsumi Y, Kabeya Y, Yamamoto A, Mizushima N, Nara A. SKD1 AAA 
ATPase-dependent endosomal transport is involved in autolysosome formation. Cell Struct 
Funct. 2002;27:29. 
35. Colombo M, Bern W, Munaf D, Gutierrez M. Rab7 is required for the normal 
progression of the autophagic pathway in mammalian cells. J Cell Sci. 2004;117:2687. 
36. Eskelinen E, Saftig P, Kominami E, et al. Role for Rab7 in maturation of late 
autophagic vacuoles. J Cell Sci. 2004;117:4837. 
37. Ohsumi , Noda , Yoshimori , et al. Autophagosome requires specific early sec proteins 
for its formation and NSF/SNARE for vacuolar fusion. Mol Biol Cell. 2001;12:3690. 
   
76 
 
38. Elazar Z, Hirschberg K, Degani I, Shvets E, Fass E. Microtubules support production 
of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. 
The Journal of biological chemistry. 2006;281:36303. 
39. Kopito R, Johnston J, Riley B, Iwata A. HDAC6 and microtubules are required for 
autophagic degradation of aggregated huntingtin. The Journal of biological chemistry. 
2005;280:40282. 
40. Mizushima N, Tokuhisa T, Ohsumi Y, et al. The role of autophagy during the early 
neonatal starvation period. Nature. 2004;432:1032. 
41. Simon H, Brunner T, Scapozza L, et al. Calpain-mediated cleavage of Atg5 switches 
autophagy to apoptosis. Nat Cell Biol. 2006;8:1124. 
42. Codogno P, Biard-Piechaczyk M, Espert L, Pattingre S. Regulation of macroautophagy 
by mTOR and beclin 1 complexes. Biochimie. 2008;90:313. 
43. Ohsumi , Yoshimori , Sugita , Mizushima . A new protein conjugation system in 
human. the counterpart of the yeast Apg12p conjugation system essential for autophagy. 
The Journal of biological chemistry. 1998;273:33889. 
44. Ohsumi , Ohsumi , Klionsky , et al. A protein conjugation system essential for 
autophagy. Nature. 1998;395:395. 
45. Ohsumi , Noda , Matsuura , Ogawa , Mizushima , Shintani . Apg10p, a novel protein-
conjugating enzyme essential for autophagy in yeast. EMBO J. 1999;18:5234. 
46. Kominami , Ohsumi , Ueno , et al. Apg7p/Cvt2p: A novel protein-activating enzyme 
essential for autophagy. Mol Biol Cell. 1999;10:1367. 
   
77 
 
47. Kominami E, Ueno T, Tanida I. LC3 conjugation system in mammalian autophagy. 
The international journal of biochemistry cell biology. 2004;36:2503. 
48. Ohsumi Y, Inagaki F, Takao T, et al. The Atg12-Atg5 conjugate has a novel E3-like 
activity for protein lipidation in autophagy. The Journal of biological chemistry. 
2007;282:37298. 
49. Yoshimori T, Noda T, Fukuda M, Omori H, Itoh T, Fujita N. The Atg16L complex 
specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell. 
2008;19:2092. 
50. Gelfand , Kuznetsov . 18 kDa microtubule-associated protein: Identification as a new 
light chain (LC-3) of microtubule-associated protein 1 (MAP-1). FEBS Lett. 1987;212:145. 
51. Ohsumi , Noda , Ohsumi , et al. A ubiquitin-like system mediates protein lipidation. 
Nature. 2000;408:488. 
52. Komatsu M, Tanaka K, Kominami E, et al. The Atg8 conjugation system is 
indispensable for proper development of autophagic isolation membranes in mice. Mol 
Biol Cell. 2008;19:4762. 
53. Ohsumi , Noda , Mizushima . Apg16p is required for the function of the Apg12p-
Apg5p conjugate in the yeast autophagy pathway. EMBO J. 1999;18:3888. 
54. Yoshimori T, Ohsumi Y, Natsume T, et al. Mouse Apg16L, a novel WD-repeat 
protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J 
Cell Sci. 2003;116:1679. 
   
78 
 
55. Xavier R, Daly M, Rioux J, Huett A, Kuballa P. Impaired autophagy of an intracellular 
pathogen induced by a crohn's disease associated ATG16L1 variant. PloS one. 
2008;3:e3391. 
56. Uchiyama Y, Kominami E, Tanaka K, et al. The MAP1-LC3 conjugation system is 
involved in lipid droplet formation. Biochem Biophys Res Commun. 2009;382:419. 
57. Ohsumi , Noda , Yoshimori , et al. Formation process of autophagosome is traced with 
Apg8/Aut7p in yeast. J Cell Biol. 1999;147:435. 
58. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of 
the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809. 
59. Levine B, Pattingre S, Byfield M, Yu J, Furuya N. The evolutionarily conserved 
domain of beclin 1 is required for Vps34 binding, autophagy and tumor suppressor 
function. Autophagy. 2005;1:46. 
60. Stenmark , Stang , D'Arrigo , et al. FYVE and coiled-coil domains determine the 
specific localisation of hrs to early endosomes. J Cell Sci. 2001;114:2255. 
61. Dixon , Taylor , Wishart . Phoxy lipids: Revealing PX domains as phosphoinositide 
binding modules. Cell. 2001;105:817. 
62. Keane R, Dietrich D, Alonso O, Bigford G. A novel protein complex in membrane 
rafts linking the NR2B glutamate receptor and autophagy is disrupted following traumatic 
brain injury. J Neurotrauma. 2009;26:703. 
63. Rabinowich H, Yin X, Stolz D, et al. Involvement of protective autophagy in TRAIL 
resistance of apoptosis-defective tumor cells. The Journal of biological chemistry. 
2008;283:19665. 
   
79 
 
64. Panaretou , Domin , Cockcroft , Waterfield . Characterization of p150, an adaptor 
protein for the human phosphatidylinositol (PtdIns) 3-kinase. substrate presentation by 
phosphatidylinositol transfer protein to the p150.ptdins 3-kinase complex. The Journal of 
biological chemistry. 1997;272:2477. 
65. Jung J, Oh B, Canaani D, et al. Autophagic and tumour suppressor activity of a novel 
Beclin1-binding protein UVRAG. Nat Cell Biol. 2006;8:688. 
66. Cecconi F, Chowdhury K, Piacentini M, et al. Ambra1 regulates autophagy and 
development of the nervous system. Nature. 2007;447:1121. 
67. Levine B, Schneider M, Packer M, et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-
dependent autophagy. Cell. 2005;122:927. 
68. Jttel M, Mathiasen I, Rizzuto R, et al. Control of macroautophagy by calcium, 
calmodulin-dependent kinase kinase-beta, and bcl-2. Mol Cell. 2007;25:193. 
69. Codogno P, Levine B, Levade T, Carpentier S, Bauvy C, Pattingre S. Role of JNK1-
dependent bcl-2 phosphorylation in ceramide-induced macroautophagy. The Journal of 
biological chemistry. 2009;284:2719. 
70. Ghidoni , Codogno , Beau , Maffei , Scarlatti . Role of non-canonical beclin 1-
independent autophagy in cell death induced by resveratrol in human breast cancer cells. 
Cell Death Differ. 2008;15:1318. 
71. Hall M, Jenoe P, Oppliger W, et al. Two TOR complexes, only one of which is 
rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457. 
   
80 
 
72. Sabatini D, Fitzgerald K, Brown M, et al. Ablation in mice of the mTORC components 
raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to akt-FOXO and 
PKCalpha, but not S6K1. Developmental cell. 2006;11:859. 
73. Sabatini D, Tempst P, Erdjument-Bromage H, et al. mTOR interacts with raptor to 
form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 
2002;110:163. 
74. Yonezawa K, Avruch J, Eguchi S, et al. Dissociation of raptor from mTOR is a 
mechanism of rapamycin-induced inhibition of mTOR function. Genes to cells. 
2004;9:359. 
75. Hay N, Sonenberg N, Skeen J, Chen C, Nogueira V, Hahn-Windgassen A. Akt 
activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK 
activity. The Journal of biological chemistry. 2005;280:32081. 
76. Pandolfi P, Tempst P, Erdjument-Bromage H, Chen Z, Ma . Phosphorylation and 
functional inactivation of TSC2 by erk implications for tuberous sclerosis and cancer 
pathogenesis. Cell. 2005;121:179. 
77. Cantley L, DePinho R, Kosmatka M, et al. The LKB1 tumor suppressor negatively 
regulates mTOR signaling. Cancer cell. 2004;6:91. 
78. Blenis J, Gygi S, Anjum R, Ballif B, Roux P. Tumor-promoting phorbol esters and 
activated ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal 
S6 kinase. Proc Natl Acad Sci U S A. 2004;101:13489. 
79. Sabatini D, Bar-Peled L, Thoreen C, et al. The rag GTPases bind raptor and mediate 
amino acid signaling to mTORC1. Science. 2008;320:1496. 
   
81 
 
80. Sabatini , Snyder , Cohen , Barrow , Burnett . RAFT1 phosphorylation of the 
translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A. 
1998;95:1432. 
81. Sonenberg , Aebersold , Hoekstra , et al. Regulation of 4E-BP1 phosphorylation: A 
novel two-step mechanism. Genes development. 1999;13:1422. 
82. Yonezawa K, Kikkawa U, Avruch J, et al. The proline-rich akt substrate of 40 kDa 
(PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. The 
Journal of biological chemistry. 2007;282:20329. 
83. Abraham R, Chiang G. Phosphorylation of mammalian target of rapamycin (mTOR) at 
ser-2448 is mediated by p70S6 kinase. The Journal of biological chemistry. 
2005;280:25485. 
84. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or 
apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. 
Cancer Res. 2006;66:10040-10047. 
85. Maeda T, Mizushima N, Noda M, et al. Isolation of hyperactive mutants of mammalian 
target of rapamycin. The Journal of biological chemistry. 2008;283:31861. 
86. Mizushima N, Oshiro N, Guan J, et al. Nutrient-dependent mTORC1 association with 
the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20:1981. 
87. Kim Y, Kwon M, Chung J, et al. Upregulation of beclin-1 expression and 
phosphorylation of bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. 
Biochem Biophys Res Commun. 2009;382:726. 
   
82 
 
88. Codogno P, Botti J, Ghidoni R, et al. Regulation of autophagy by sphingosine kinase 1 
and its role in cell survival during nutrient starvation. The Journal of biological chemistry. 
2006;281:8518. 
89. Schwartz G, Merrill A, Wang E, et al. Safingol (L-threo-sphinganine) induces 
autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. 
Autophagy. 2009;5:184. 
90. Kaufman R, Wu J, Sakaki K. Protein kinase ctheta is required for autophagy in 
response to stress in the endoplasmic reticulum. The Journal of biological chemistry. 
2008;283:15370. 
91. Kroemer G, Lavandero S, Maiuri , Tasdemir E, Vicencio J, Criollo A. The inositol 
trisphosphate receptor in the control of autophagy. Autophagy. 2007;3:350. 
92. Sabatini D, Fitzgerald K, Brown M, et al. Ablation in mice of the mTORC components 
raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to akt-FOXO and 
PKCalpha, but not S6K1. Developmental cell. 2006;11:859. 
93. Su B, Qin J, Huang Q, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and 
regulates akt phosphorylation and substrate specificity. Cell. 2006;127:125. 
94. Magnuson M, Shelton K, Lindner J, Woo J, Shiota C. Multiallelic disruption of the 
rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. 
Developmental cell. 2006;11:583. 
95. Sabatini D, Ali S, Guertin D, Sarbassov . Phosphorylation and regulation of Akt/PKB 
by the rictor-mTOR complex. Science. 2005;307:1098. 
   
83 
 
96. Jacinto E, Su B, Zhang P, et al. The mammalian target of rapamycin complex 2 
controls folding and stability of akt and protein kinase C. EMBO J. 2008;27:1932. 
97. Sabatini D, Tempst P, Erdjument-Bromage H, et al. Rictor, a novel binding partner of 
mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton. Current biology. 2004;14:1296. 
98. Hall M, Hall A, Regg M, et al. Mammalian TOR complex 2 controls the actin 
cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122. 
99. Sandri M, Schiaffino S, Goldberg A, et al. FoxO3 controls autophagy in skeletal 
muscle in vivo. Cell metabolism. 2007;6:458. 
100. Harris , Greenberg , Watson , Ratcliffe , Sowter . HIF-1-dependent regulation of 
hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 
2001;61:6669. 
101. Schrder . Endoplasmic reticulum stress responses. Cellular and molecular life 
sciences. 2008;65:862. 
102. Momoi , Kominami , Kaufman , et al. ER stress (PERK/eIF2alpha phosphorylation) 
mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy 
formation. Cell Death Differ. 2007;14:230. 
103. Johnson J, Lin Y, Yang T, Gwiazda K. Effects of palmitate on ER and cytosolic Ca2 
homeostasis in beta-cells. American journal of physiology: endocrinology and metabolism. 
2009;296:E690. 
   
84 
 
104. Pagliassotti , Gentile , Wang , Wei . Reduced endoplasmic reticulum luminal calcium 
links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver 
cells. Mol Cell Biochem. 2009. 
105. Hendershot L, Diehl , Brewer J, Ma Y. Two distinct stress signaling pathways 
converge upon the CHOP promoter during the mammalian unfolded protein response. J 
Mol Biol. 2002;318:1351. 
106. Mori , Yura , Yanagi , Yoshida , Haze . Mammalian transcription factor ATF6 is 
synthesized as a transmembrane protein and activated by proteolysis in response to 
endoplasmic reticulum stress. Mol Biol Cell. 1999;10:3787. 
107. Niwa M, Tam A, DuRose J. Intrinsic capacities of molecular sensors of the unfolded 
protein response to sense alternate forms of endoplasmic reticulum stress. Mol Biol Cell. 
2006;17:3095. 
108. Lee , Hinton , Barron , Lee , Ni , Li . The unfolded protein response regulator 
GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy 
in mammalian cells. Cell Death Differ. 2008;15:1460. 
109. Jttel , Hyer-Hansen . Connecting endoplasmic reticulum stress to autophagy by 
unfolded protein response and calcium. Cell Death Differ. 2007;14:1576. 
110. Imaizumi K, Urano F, Hammarback J, et al. Autophagy is activated for cell survival 
after endoplasmic reticulum stress. Mol Cell Biol. 2006;26:9220. 
111. Rizzuto , Pozzan , Campanella , et al. Endoplasmic reticulum, bcl-2 and Ca2 handling 
in apoptosis. Cell Calcium. 2002;32:413. 
   
85 
 
112. Brenner , Lemaire , Kroemer , et al. Endoplasmic reticulum stress induces calcium-
dependent permeability transition, mitochondrial outer membrane permeabilization and 
apoptosis. Oncogene. 2008;27:285. 
113. Kimchi A, Shani G, Sabanay I, Bialik S, Inbal B. DAP kinase and DRP-1 mediate 
membrane blebbing and the formation of autophagic vesicles during programmed cell 
death. J Cell Biol. 2002;157:455. 
114. Williams A, Sarkar S, Cuddon P, et al. Novel targets for huntington's disease in an 
mTOR-independent autophagy pathway. Nature Chemical Biology. 2008;4:295. 
115. Spiegel , Brooker , Seki , Olivera , Desai , Zhang . Sphingosine-1-phosphate, a novel 
lipid, involved in cellular proliferation. J Cell Biol. 1991;114:155. 
116. Spiegel , Olivera . Sphingosine-1-phosphate as second messenger in cell proliferation 
induced by PDGF and FCS mitogens. Nature. 1993;365:557. 
117. Spiegel , Gutkind , Coso , et al. Suppression of ceramide-mediated programmed cell 
death by sphingosine-1-phosphate. Nature. 1996;381:800. 
118. Spiegel , Milstien , Hobson , Rosenfeldt . The sphingosine-1-phosphate receptor 
EDG-1 is essential for platelet-derived growth factor-induced cell motility. Biochem Soc 
Trans. 2001;29:836. 
119. Goetzl E, Graeler M. Activation-regulated expression and chemotactic function of 
sphingosine 1-phosphate receptors in mouse splenic T cells. The FASEB journal. 
2002;16:1874. 
120. Takuwa Y, Sakurada S, Okamoto H, Takuwa N, Sugimoto N. Inhibitory and 
stimulatory regulation of rac and cell motility by the G12/13-rho and gi pathways 
   
86 
 
integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor 
isoform. Mol Cell Biol. 2003;23:1534. 
121. Proia , Spiegel , Hla , et al. Edg-1, the G protein-coupled receptor for sphingosine-1-
phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951. 
122. English , Bamberg , Gerthoffer , et al. Sphingosine 1-phosphate promotes endothelial 
cell barrier integrity by edg-dependent cytoskeletal rearrangement. J Clin Invest. 
2001;108:689. 
123. Cyster J, Schwab S. Finding a way out: Lymphocyte egress from lymphoid organs. 
Nat Immunol. 2007;8:1295. 
124. Trnquist K, Pitson S, Slotte , Blom T. Enhancement of intracellular sphingosine-1-
phosphate production by inositol 1,4,5-trisphosphate-evoked calcium mobilisation in 
HEK-293 cells: Endogenous sphingosine-1-phosphate as a modulator of the calcium 
response. Cell Signal. 2005;17:827. 
125. Milstien S, Spiegel S. Sphingosine-1-phosphate: An enigmatic signalling lipid. 
Nature Reviews.Molecular Cell Biology. 2003;4:397. 
126. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ. Tipping the gatekeeper: S1P 
regulation of endothelial barrier function. Trends Immunol. 2007;28:102-107. 
127. Sternweis P, Fraser I, Taussig R, et al. Use of a cAMP BRET sensor to characterize a 
novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. The Journal of 
biological chemistry. 2007;282:10576. 
   
87 
 
128. Takashima S, Sugimoto N, Takuwa N, et al. G12/13 and gq mediate S1P2-induced 
inhibition of rac and migration in vascular smooth muscle in a manner dependent on rho 
but not rho kinase. Cardiovasc Res. 2008;79:689-697. 
129. Björklund S, Palmberg S, Rask S, Westerdahl A, Törnquist K. Effects of sphingosine 
1-phosphate on calcium signaling, proliferation and S1P2 receptor expression in PC Cl3 rat 
thyroid cells. Mol Cell Endocrinol. 2005;231:65-74. 
130. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists 
from high- throughput screening: Off-the-shelf chemical probes of receptor interactions, 
signaling, and fate. Chem Biol. 2005;12:703-715. 
131. Lee M, Thangada S, Paik J, et al. Akt-mediated phosphorylation of the G protein-
coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001;8:693-
704. 
132. Spiegel S, Milstien S, Beaven M, Payne S, Oskeritzian C, Mitra P. Role of ABCC1 in 
export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 
2006;103:16394. 
133. Pagano , Hubbard , Stieger , Futerman . Sphingomyelin synthesis in rat liver occurs 
predominantly at the cis and medial cisternae of the golgi apparatus. The Journal of 
biological chemistry. 1990;265:8650. 
134. Hannun , Kolesnick . Ceramide and apoptosis. Trends Biochem Sci. 1999;24:224. 
135. Fabris , Ghidoni , Casas , Gagliostro , Munoz-Olaya , Signorelli . Dihydroceramide 
intracellular increase in response to resveratrol treatment mediates autophagy in gastric 
cancer cells. Cancer Lett. 2009. 
   
88 
 
136. Sandhoff , Pfeilschifter , Kolter , Huwiler . Physiology and pathophysiology of 
sphingolipid metabolism and signaling. Biochim Biophys Acta. 2000;1485:63. 
137. Hannun Y, Ogretmen B. Biologically active sphingolipids in cancer pathogenesis and 
treatment. Nature Reviews.Cancer. 2004;4:604. 
138. Nishijima M, Fukasawa M, Kawano M, et al. Molecular machinery for non-vesicular 
trafficking of ceramide. Nature. 2003;426:803. 
139. Holthuis , van Meer . Sphingolipid transport in eukaryotic cells. Biochim Biophys 
Acta. 2000;1486:145. 
140. Obeid L, Hannun Y. Principles of bioactive lipid signalling: Lessons from 
sphingolipids. Nature Reviews.Molecular Cell Biology. 2008;9:139. 
141. De Matteis M, Mattjus P, Polishchuk R, et al. Glycosphingolipid synthesis requires 
FAPP2 transfer of glucosylceramide. Nature. 2007;449:62. 
142. Hannun Y, Obeid L, Mao C, el Bawab S. Ceramidases in the regulation of ceramide 
levels and function. Subcell Biochem. 2002;36:187. 
143. Obeid L, Hannun Y. The ceramide-centric universe of lipid-mediated cell regulation: 
Stress encounters of the lipid kind. The Journal of biological chemistry. 2002;277:25847. 
144. Hannun , Kolesnick . Ceramide and apoptosis. Trends Biochem Sci. 1999;24:224. 
145. Spiegel S, Mandala S, Milstien S, Thornton R, Peterson C, Le Stunff H. 
Characterization of murine sphingosine-1-phosphate phosphohydrolase. The Journal of 
biological chemistry. 2002;277:8920. 
   
89 
 
146. Igarashi Y, Gokoh M, Kihara A, Ogawa C. Identification and characterization of a 
novel human sphingosine-1-phosphate phosphohydrolase, hSPP2. The Journal of 
biological chemistry. 2003;278:1268. 
147. Riezman H, Futerman A. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 
2005;15:312. 
148. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role 
for sphingosine kinases in neural and vascular development. Mol Cell Biol. 
2005;25:11113-11121. 
149. Spiegel , Kohama , Milstien , et al. Molecular cloning and functional characterization 
of a novel mammalian sphingosine kinase type 2 isoform. The Journal of biological 
chemistry. 2000;275:19513. 
150. Spiegel S, Milstien S, Chun J, et al. Sphingosine kinase type 2 is a putative BH3-only 
protein that induces apoptosis. The Journal of biological chemistry. 2003;278:40330. 
151. Nakamura S, Jahangeer S, Miwa N, et al. Involvement of N-terminal-extended form 
of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. 
The Journal of biological chemistry. 2005;280:36318. 
152. Billich A, Baumruker T, Bornancin F, et al. Sphingosine kinase type 2 is essential for 
lymphopenia induced by the immunomodulatory drug FTY720. Blood. 2006;107:1454. 
153. Proia R, Spiegel S, Mandala S, et al. Mice deficient in sphingosine kinase 1 are 
rendered lymphopenic by FTY720. The Journal of biological chemistry. 2004;279:52487. 
   
90 
 
154. Lynch K, Pearson-White S, Macdonald T, et al. Sphingosine kinase 2 is required for 
modulation of lymphocyte traffic by FTY720. The Journal of biological chemistry. 
2005;280:36865. 
155. Spiegel S, Milstien S, Chun J, et al. Sphingosine kinase type 2 is a putative BH3-only 
protein that induces apoptosis. The Journal of biological chemistry. 2003;278:40330. 
156. Spiegel S, Milstien S, Dent P, et al. Involvement of sphingosine kinase 2 in p53-
independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res. 
2007;67:10466. 
157. Vadas M, Wattenberg B, Lynn H, et al. Phosphorylation-dependent translocation of 
sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 
2005;201:49. 
158. Raben D, Pitson S, Wattenberg B. The sphingosine and diacylglycerol kinase 
superfamily of signaling kinases: Localization as a key to signaling function. J Lipid Res. 
2006;47:1128. 
159. Cho W, Obeid L, Johnson K, et al. The mechanism of membrane targeting of human 
sphingosine kinase 1. The Journal of biological chemistry. 2005;280:43030. 
160. Spiegel , Milstien , Caron , et al. Role of the sphingosine-1-phosphate receptor EDG-1 
in PDGF-induced cell motility. Science. 2001;291:1800. 
161. Broek D, Mosteller R, Wu W, Shu X. Sphingosine kinase mediates vascular 
endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. 
Mol Cell Biol. 2002;22:7758. 
   
91 
 
162. Spiegel S, Milstien S, Sankala H, et al. Sphingosine kinase 1 is required for migration, 
proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 2005;579:5313. 
163. Wang L, Lu Z, Jia X, et al. Sphingosine kinase activation regulates hepatocyte growth 
factor induced migration of endothelial cells. Exp Cell Res. 2004;298:593. 
164. Vadas M, Gamble J, D'Andrea R, et al. Sphingosine kinase interacts with TRAF2 and 
dissects tumor necrosis factor-alpha signaling. The Journal of biological chemistry. 
2002;277:7996. 
165. Xia , Vadas M, Pitson S, Albanese N, Wang L, Sukocheva O. Sphingosine kinase 
transmits estrogen signaling in human breast cancer cells. Molecular endocrinology. 
2003;17:2002. 
166. Carpenter , Sukocheva . Anti-apoptotic effects of 3,5,3'-tri-iodothyronine in mouse 
hepatocytes. J Endocrinol. 2006;191:447. 
167. Ktistakis N, Pyne S, Krugmann S, et al. Sphingosine kinase 1 is an intracellular 
effector of phosphatidic acid. The Journal of biological chemistry. 2004;279:44763. 
168. Jakobs , Rmenapp , Alemany , et al. Stimulation of intracellular sphingosine-1-
phosphate production by G-protein-coupled sphingosine-1-phosphate receptors. Eur J 
Pharmacol. 2001;414:145. 
169. Spiegel S, Milstien S, Alvarez S. Autocrine and paracrine roles of sphingosine-1-
phosphate. Trends in Endocrinology and Metabolism. 2007;18:300. 
170. Wattenberg , D'Andrea , Vadas , et al. Expression of a catalytically inactive 
sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A 
   
92 
 
dominant-negative sphingosine kinase. The Journal of biological chemistry. 
2000;275:33945. 
171. Vadas , Gamble , Wang , Xia . Activation of sphingosine kinase by tumor necrosis 
factor-alpha inhibits apoptosis in human endothelial cells. The Journal of biological 
chemistry. 1999;274:34499. 
172. Pitson S, Vadas M, Bagley C, Hewitt N, Moretti PAB, Sutherland C. The calmodulin-
binding site of sphingosine kinase and its role in agonist-dependent translocation of 
sphingosine kinase 1 to the plasma membrane. The Journal of biological chemistry. 
2006;281:11693. 
173. Igarashi Y, Wada A, Aoyama Y, Fukuda . Identification of PECAM-1 association 
with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. Biochim 
Biophys Acta. 2004;1636:12. 
174. Nakamura S, Miwa N, Jahangeer S, Hayashi S, Okada T, Fujita T. Delta-
catenin/NPRAP (neural plakophilin-related armadillo repeat protein) interacts with and 
activates sphingosine kinase 1. Biochem J. 2004;382:717. 
175. Spiegel S, Milstien S, Nava V, Maceyka M. Aminoacylase 1 is a sphingosine kinase 
1-interacting protein. FEBS Lett. 2004;568:30. 
176. Spiegel S, Milstien S, Maceyka M, Lacan E. Cloning and characterization of a protein 
kinase A anchoring protein (AKAP)-related protein that interacts with and regulates 
sphingosine kinase 1 activity. The Journal of biological chemistry. 2002;277:32947. 
   
93 
 
177. Nakamura S, Jahangeer S, Fujita T, Igarashi N, Okada T, Hayashi S. Identification 
and characterization of RPK118, a novel sphingosine kinase-1-binding protein. The 
Journal of biological chemistry. 2002;277:33319. 
178. Obeid L, Hannun Y, Dbaibo G, et al. Down-regulation of sphingosine kinase-1 by 
DNA damage: Dependence on proteases and p53. The Journal of biological chemistry. 
2004;279:20546. 
179. Obeid L, Hannun Y, Bielawski J, El-Alwani M, Kitatani K, Taha T. Loss of 
sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: Modulation 
of sphingolipid levels and the induction of apoptosis. The FASEB journal. 2006;20:482. 
180. Geilen C, Spiegel S, Eberle J, Mller C, Jolly P, Bektas M. Sphingosine kinase activity 
counteracts ceramide-mediated cell death in human melanoma cells: Role of bcl-2 
expression. Oncogene. 2005;24:178. 
181. Prior T, Snyder P, Kotur M, Pearl D, Jackson C, Van Brocklyn J. Sphingosine kinase-
1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles 
of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp 
Neurol. 2005;64:695. 
182. Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy 
sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005;65:11667-
11675. 
183. Codogno P, Ghidoni R, Vandewalle A, et al. Ceramide-mediated macroautophagy 
involves inhibition of protein kinase B and up-regulation of beclin 1. The Journal of 
biological chemistry. 2004;279:18384. 
   
94 
 
184. Spiegel S, Grant S, Zipkin R, et al. A selective sphingosine kinase 1 inhibitor 
integrates multiple molecular therapeutic targets in human leukemia. Blood. 
2008;112:1382. 
185. Yoshimori , Ohsumi , Kominami , et al. LC3, a mammalian homologue of yeast 
Apg8p, is localized in autophagosome membranes after processing. EMBO J. 
2000;19:5720. 
186. Mizushima N, Matsui M, Kuma A. LC3, an autophagosome marker, can be 
incorporated into protein aggregates independent of autophagy: Caution in the 
interpretation of LC3 localization. Autophagy. 2007;3:323. 
187. Kroemer G, Criollo A, Morselli E, et al. p53 represses autophagy in a cell cycle-
dependent fashion. Cell cycle. 2008;7:3006. 
188. Cantley L, Shaw R. Ras, PI(3)K and mTOR signalling controls tumour cell growth. 
Nature. 2006;441:424. 
189. Raymond E, Djelloul S, Faivre S. New paradigms in anticancer therapy: Targeting 
multiple signaling pathways with kinase inhibitors. Semin Oncol. 2006;33:407. 
190. Brown , Hui , Matter , Vlahos . A specific inhibitor of phosphatidylinositol 3-kinase, 
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). The Journal of 
biological chemistry. 1994;269:5241. 
191. Lee , Hinton , Barron , Lee , Ni , Li . The unfolded protein response regulator 
GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy 
in mammalian cells. Cell Death Differ. 2008;15:1460. 
   
95 
 
192. Cavener D, Zhang P, McGrath B, Zhang W, Liang S. PERK (eIF2alpha kinase) is 
required to activate the stress-activated MAPKs and induce the expression of immediate-
early genes upon disruption of ER calcium homoeostasis. Biochem J. 2006;393:201. 
193. Mather , Bauer , Donahue , Moore . Simultaneous measurement of cell cycle and 
apoptotic cell death. Methods Cell Biol. 1998;57:265. 
194. Berneman Z, Van Bockstaele D, Vermeulen K. Apoptosis: Mechanisms and relevance 
in cancer. Ann Hematol. 2005;84:627. 
195. Kroemer G, Cecconi F, Codogno P, et al. Regulation of autophagy by cytoplasmic 
p53. Nat Cell Biol. 2008;10:676. 
196. Kim Y, Kwon M, Chung J, et al. Upregulation of beclin-1 expression and 
phosphorylation of bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. 
Biochem Biophys Res Commun. 2009;382:726. 
197. Kroemer G, Tavernarakis N, Cecconi F, et al. A dual role of p53 in the control of 
autophagy. Autophagy. 2008;4:810. 
198. Dragusin M, Gurgui C, Schwarzmann G, Hoernschemeyer J, van Echten-Deckert G. 
Metabolism of the unnatural anticancer lipid safingol, L-threo-dihydrosphingosine, in 
cultured cells. J Lipid Res. 2003;44:1772-1779. 
199. Colombini , Fistere , Stiban . Dihydroceramide hinders ceramide channel formation: 
Implications on apoptosis. Apoptosis. 2006;11:773. 
200. Maceyka M, Alvarez SE, Milstien S, Spiegel S. Filamin A links sphingosine kinase 1 
and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol 
Cell Biol. 2008;28:5687-5697. 
   
96 
 
201. Im D, Kim H. N, N-dimethyl-D-erythro-sphingosine increases intracellular Calcium 
concentration via Na Calcium exchanger in HCT116 human colon cancer cells. Arch 
Pharm Res. 2008;31:54. 
 
 
 
   
97 
 
 
 
 
 
 VITA 
 
 Daniel Meza is an unorthodox student of science, having devoted himself 
previously to the education of children.  It is his hope that the investigative abilities he has 
learned as a student of Biochemistry and Molecular Biology will enhance his ability to 
serve children by using these scientific tools and methodologies.  
 
